The University of San Francisco

USF Scholarship: a digital repository @ Gleeson Library |
Geschke Center
Doctoral Dissertations

Theses, Dissertations, Capstones and Projects

Summer 8-1-2018

Entropy as a Method for Identifying Treatment
Resistant Autism Spectrum Disorder
Nathan Wright
nwright4@dons.usfca.edu

Follow this and additional works at: https://repository.usfca.edu/diss
Part of the Clinical Psychology Commons, and the Developmental Psychology Commons
Recommended Citation
Wright, Nathan, "Entropy as a Method for Identifying Treatment Resistant Autism Spectrum Disorder" (2018). Doctoral Dissertations.
439.
https://repository.usfca.edu/diss/439

This Dissertation is brought to you for free and open access by the Theses, Dissertations, Capstones and Projects at USF Scholarship: a digital
repository @ Gleeson Library | Geschke Center. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of USF
Scholarship: a digital repository @ Gleeson Library | Geschke Center. For more information, please contact repository@usfca.edu.

Running head: ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

Entropy as a Method for Identifying
Treatment Resistant Autism Spectrum Disorder

A Clinical Dissertation Presented to
The University of San Francisco
School of Nursing and Health Professions
Department of Integrated Healthcare
PsyD Program in Clinical Psychology

In Partial Fulfillment of the Requirements for the Degree
Doctor of Psychology

By
Nathan Andrew Wright
June, 2018

1

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

2

Abstract
Background: Individuals diagnosed with Autism Spectrum Disorder (ASD) experience lifelong
challenges which can impact peer relationships, adaptive functioning, and independent living.
Verbal intelligence has proven to be the strongest indicator of outcomes and responsiveness to
behavioral intervention, but this property only stabilizes in children between 6 and 8 years of
age. Behavioral treatment is the primary intervention for individuals diagnosed with ASD, but it
is most effective when delivered as an early intervention strategy for toddlers and very young
children. A biomarker which could distinguish treatment resistant subgroups of ASD from would
allow for the development and implementation of alternative treatments in an attempt to improve
long term outcomes.
Methods: Our study used data from 49 participants made available through the National
Database for Autism Research (NDAR). The sample group contained children between 4 and 11
years of age diagnosed with ASD and typically developing peers. Our study used EEG and
behavioral measures to explore whether sample entropy analysis of EEG, as developed by Bosl
et al. (2011), could distinguish between individuals with ASD and low verbal IQ from their
average verbal and typically developing peers.
Results: The analysis we performed found that higher levels of sample entropy were correlated
with lower ASD symptoms and better adaptive functioning. ANOVA analysis also suggested
that sample entropy could distinguish ASD and typically developing children. Sample entropy
was not correlated with verbal IQ and could not distinguish the ASD low verbal IQ group from
both ASD with average verbal IQ and typically developing groups.
Conclusion: Researchers interested in identifying biomarkers for treatment resistant ASD should
look beyond sample entropy for reliable measures. Sample entropy does appear to play a role in
autistic symptomatology, and greater research into its role as a possible indicator of underlying
neurological abnormalities should be explored. Researchers may also find value in including
sample entropy in longitudinal studies to see how this measure changes with behavioral
improvements as a result of behavioral treatment.
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Introduction
The Most Pressing Need
Individuals diagnosed with Autism Spectrum Disorder (ASD) experience a range of
challenges later in life as a result of their neurodevelopmental condition. These challenges range
from limited peer interaction, high rates of joblessness, and difficulties managing the demands of
independent living. Estimates of individuals with ASD facing significant challenges in these
domains can be as high as 58% (Howlin, Goode, Hutton, & Rutter, 2004). The fundamental
problem facing clinicians and researchers working with ASD is how to improve outcomes for
this group.
While investigation into the biology of ASD are ongoing, there is no well-defined
etiology and no reliable pharmacological interventions that target the core symptoms of ASD.
Behavioral interventions emphasizing early detection and treatment of ASD have proved
effective, however, outcomes remain poor for many who do not respond as well to these
interventions as their peers (Eikeseth, 2009). The problem with this situation is that children who
do not response positively to behavioral intervention have wasted an important developmental
window wherein treatment is deemed most effective. This has led researchers to investigate early
markers that might indicate how a child might respond to behavioral intervention.
The most reliable predictor of outcomes in ASD is verbal intelligence. The influence of
this factor has been demonstrated in numerous studies (Anderson, Liang, & Lord, 2014; Lord,
Bishop, & Anderson, 2015; Kim, Bal, & Lord, 2018), and verbal ability has also been shown to
be an important factor correlated with responsiveness to behavioral intervention (Fossum,
Williams, Garon, Bryson, & Smith, 2018).Instruments such as the Mullen Scales of Early
Learning are used to measure intelligence in very young children with ASD, however, behavioral
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measures of intelligence at this age are unreliable, with correlation between IQ at age one and
fifteen being as low as r=.15 (Gottfried, Gottfried, & Guerin, 2009). Intelligence is generally
believed to stabilize between the ages of 6 and 8, casting doubt upon the reliability of IQ
measures for children as method of detecting responsiveness to intervention, or predicting later
outcomes.
Biological measures that can be reliably implemented, can predict responsiveness to
intervention, and are correlated with outcomes later in life would be an invaluable contribution to
this field. These measures could allow for the early detection of treatment resistant ASD,
allowing for novel interventions to be administered during the crucial developmental window
associated with better outcomes. Our study investigates whether an early biomarker of ASD may
be sensitive to low verbal IQ, a feature associated with poor outcomes in children diagnosed with
ASD.
Literature review
Autism Defined.
In 2012 ASD in the United States had a prevalence rate among 8-year-old children of 1 in
68. Prevalence among boys is higher, with 1 in 42 boys receiving the diagnosis compared to 1 in
189 in girls (Christensen, Baio, & Braun, 2016; Center for Disease Control, 2014). ASD is
defined behaviorally in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) and can presently only be diagnosed through behavioral observation. The disorder is
categorized by deficits in social communication and the presence of restrictive and repetitive
behaviors. Social communication and social interaction deficits can affect the performance of
nonverbal communication, reciprocal engagement, and the development of interpersonal
relationships. Restrictive and repetitive behaviors can include stereotyped motor movements,

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

5

inflexible adherence to routines, restricted interests, and sensitivity to sensory stimuli (American
Psychiatric Association, 2013).
Although ASD is diagnosed through behavioral observation, it is assumed to be rooted in
the biology of individuals with the condition. Advances in research investigating the etiology of
ASD have led to the proposal that ASD be conceptualized as a neurodevelopmental disorder,
highlighting its biological foundations (Insel, 2014). The systems implicated in ASD are varied,
ranging from from immunology (Masi et al, 2015) to gastrointestinal problems (Vissoker, Latzer
& Gal, 2015). The most common and heavily researched domains, however, are genetics and
neuroscience (Insel, 2014). Research into the genetic underpinnings of ASD has discovered
several genetic abnormalities responsible for clusters of individuals with the condition, and
neuroscience research has discovered possible neural systems and processes which may be
responsible for the symptoms of ASD.
Genetics.
The genomic underpinning of ASD is evidenced by the strong correlation of ASD
between siblings, specifically between monozygotic twins (Tick et al.,2016). Despite positive
indications for the genetic causes of ASD, specific genomic disturbances can only account for
approximately 5% of cases. Three specific genetic disorders present with the behavioral
symptoms typical of ASD, namely, Rett Syndrome, 22q11.2 Deletion Syndrome (22q11DS) and
Klinefelter Syndrome. All three of these disorders are excluded from the ASD category precisely
because they are understood as discrete genetic conditions (Miyake et al., 2011; Manning et al.,
2004; Biswas & Furniss, 2016; van Rijn, 2015).
These genetic conditions present with behavioral profiles consistent with ASD and shed
light on the problem of heterogeneity in the field. ASD is a broad phenotype that has made
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classification using behavioral diagnostic rubrics difficult (Tsai & Ghaziuddin 2013; Young &
Rodi 2013). Genetic research into the etiology of ASD aims to deal with this heterogeneity by
identifying discrete genetic conditions responsible for distinct symptom clusters. Research has
shown that isolation of 22q11DS and Klinefelter Syndrome within a broader group of individuals
diagnosed with ASD significantly decreases phenotypic heterogeneity of the sample (Bruining et
al., 2010). This raises the hope that ASD may be understood as a collection of rare genetic
disorders, each responsible for a cluster of symptoms within the autism spectrum.
Unfortunately, specific genetic explanations for ASD remain elusive aside from the cases
discussed above. The ability of genetics to explain phenotypic heterogeneity appears to have its
limits. Chaste et al. (2014) collected a sample of individuals with ASD to explore the
relationship between genetics and phenotypic heterogeneity. The researchers in this study
divided the sample into clusters based upon behavior profiles to create homogenous subgroups.
Then, they compared the genetic makeup between groups to see if genetic heterogeneity had
likewise been reduced, but it had not. While the possibility of distinct subgroups within ASD
remain, with strict adherents of this position using the term “autisms” (Cantio, et al., 2016),
genetics alone cannot currently define this heterogeneous condition.
While the genetic disorders discussed above identify gene abnormalities as the ultimate,
or distal, cause of ASD symptomatology, they implicate neural functioning as the proximate
cause of ASD behavior profiles. Rett Syndrome, for example, results from a mutation in the
MeCP2 gene which in turn influences the expression of genes essential for brain development
(Miyake et al., 2011). 22q11DS also results in structural and connective abnormalities in the
brain, as well as abnormalities in neurotransmitters such as COMT (Biswas & Furniss 2016).
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The impact these genetic disorders have on neural development suggest that the brain may be an
additional candidate system for research into the etiology of ASD.
Neuroscience.
The majority of ASD cases are idiopathic, where no clear genetic or environmental cause
for the disorder has been identified. In these cases, the role of neural systems is paramount,
because it provides insight into the mechanisms which underpin aberrant behavior, regardless of
the ultimate underlying cause. Research in the neuroscience of ASD can be generally divided by
the technology used to investigate the neural system. The most common neuroimaging
techniques are computed tomography (CT), magnetic resonance imaging (MRI), functional
magnetic resonance imaging (fMRI), and electroencephalography (EEG). Abnormalities in both
structure and function of neural systems are investigated by these technologies, with CT and
MRI used to detect structural abnormalities, and fMRI and EEG used to detect abnormalities in
functioning.
Research has discovered abnormalities in several brain regions and networks that are
implicated in ASD. CT scans have contributed to our understanding of neurobiological
underpinnings of ASD (Eigsti & Schuh, 2008), and MRI research has been used to inform
changes in diagnostic criteria of ASD (Pina-Camacho et al., 2013). Structural abnormalities have
been detected in nearly every region of the brain for individuals with ASD, and these varied
results are presumed to be the byproduct of the heterogeneity of the condition itself (Sivapalan &
Aitchison, 2014). Differences are usually determined by greater volume in white or grey matter,
and a larger volume of neural matter is general found in individuals with ASD. The wide range
of brain regions implicated in ASD has led researchers to look beyond the structure of the brain
and turn their focus to the networks which connect these regions (Sivapalan & Aitchison, 2014).
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Connectivity between brain regions is often established using fMRI measurements, and
this has become a leading method for investigating neural system in ASD. Due to its spatial
resolution of 2-3 millimeters and the ability to monitor neural processing by detecting changes in
blood flow associated with neural activation, it is a well-suited method for examining neural
connectivity. fMRI studies have discovered abnormal functioning in the ventral visual cortex,
prefrontal cortex, anterior cingulate in individuals with ASD (Ewbank et al., 2015; Solomon et
al., 2015). An emerging field of inquiry has also implicated the cerebellum and its functional
connectivity to other neural structures (Crippa et al., 2016). While fMRI explores connectivity
between brain regions by measuring blood flow, EEG can measure connectivity at a finer
timescale and record the most salient phenomenon in neural networks, namely, the action
potential and resulting electrical activity.
An early indication that ASD may involve abnormalities in the brain’s electrical patterns
was suggested by the high comorbidity between ASD and Epilepsy (Kanner, 2000). These two
conditions are diagnostically distinct, but researchers have explored the clinical significance of
individuals presenting with both conditions, finding that the presence of Epilepsy in conjunction
with ASD is associated with more severe symptomatology and poorer treatment outcomes
(Viscidi et al., 2013; Schubarata et al., 2015; El Achkar and Spence, 2015). Additional research
has shown that epileptiform patterns of electrical activity are present in ASD, even in the absence
of Epilepsy (Spence & Schneider, 2009; Boutros et al. 2015). Bosl, Loddenkemper & Nelson
(forthcoming) found that specific methods of nonlinear analysis can be used to distinguish ASD,
Epilepsy, and healthy controls, but that the ASD population represented a midpoint between
Epilepsy and control groups, suggesting that ASD and Epilepsy may share a common pathology,
with ASD being a moderate form of the later. In addition to the similarities between ASD and
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epilepsy, more traditional EEG measurements have found abnormalities in a variety of areas
including gamma oscillations, theta and beta power spectra and interhemispheric connectivity
(Maxwell et al., 2015; Bink et al., 2015; Machado et al., 2015; Lazarev et al., 2015;).
Developmental Trajectories.
Research into the genetics and neuroscience of ASD continues investigating the
mechanisms of action and discrete causes of this disorder, but the condition is still diagnosed
behaviorally. Behavioral conceptions of ASD have evolved over the past few years, in part
reflecting the discoveries from genetics and neuroscience regarding the etiology of the disorder.
From a behavioral perspective, the continuity of ASD as a singular disorder has been challenged
in the research literature (Georgiades et al. 2013; Tek, Mesite, Fein, & Naigles 2013; Sullivan,
Daly, & O’Donovan 2012; Jeste & Geschwind 2014; Happé, Ronald, & Plomin, 2006). The
broad phenotype of ASD has made it difficult to classify using behavioral diagnostic rubrics
(Tsai and Ghaziuddin 2013; Young and Rodi 2013). The recent transition from the DSM-IV-TR
to the DSM-5 involved significant changes to the categorization of ASD, and were in part
motivated by the heterogeneity of the disorder. While the DSM-IV provided separate diagnostic
criteria for Autistic Disorder, Asperger’s Disorder and Pervasive Developmental Disorder Not
Otherwise Specified, the DSM-5 realigns these categories into one umbrella diagnosis – ASD.
The unification of this diagnostic criteria has been met with some resistance from
researchers who support the discrete categories of the DSM-IV-TR, arguing they identify
clinically useful subgroups (Tsai & Ghaziuddin 2013). A survey of the literature does reveal
some distinct phenotypes between the DSM-IV-TR categories (Tsai & Ghaziuddin 2013), but
advocates of the DSM-5 criteria cite broad overlap of symptoms and the absence of evidence for
distinct biological etiologies to justify the spectrum model (Young & Rodi 2013). Those who
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favor the DSM-5 changes do not endorse a homogeneous view of ASD, but instead argue that
discrete categories without biological justification are invalid (Young & Rodi 2013). In this case,
no categories are better than false categories. Broad support exists on both sides of the debate
that ASD is a heterogeneous disorder, the disagreement is simply around what role biological
considerations should play in diagnosis (Tsai & Ghaziuddin 2013; Young & Rodi 2013).
While the DSM-5 has taken an important step in abandoning discrete categories not
supported by biological research, more work needs to be done to identify clinically useful
subgroups of the autism spectrum. The most promising behavioral research with this goal
proposes developmental trajectories, which account for individual change over time, as a
potential method for dividing ASD into meaningful subgroups (Venker et al., 2014). Foss-Feig et
al. (2016) make the most explicit endorsement for this transition and argue that a model which
clusters symptoms along positive, negative and cognitive features would help capture
development over time. More traditional models of lifespan development have also been
suggested as suitable for the purpose of generating developmental trajectories for ASD (Franklin
et al., 2015). In both cases authors are advocating for perspectives in which ASD is flexible, not
only in terms of symptom severity, but also in terms of change over time.
Developmental trajectories based on behavioral data have the advantage of incorporating
clinical concerns into what would otherwise a science of taxonomy. By collecting and examining
longitudinal behavioral data, researchers can explore which factors in early development are
associated with better or worse outcomes, as well as responsiveness to intervention. Statistical
methods such as group-based trajectory modeling have been employed to identify subgroups of
the autism spectrum based on changes in symptomatology over time (Fountain, Winter, &
Bearman, 2012). This research, however, does not address the critical issue of identifying
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individuals with ASD who experience poor outcomes and do not respond favorably to treatment.
Serious engagement with the research around treatment of ASD highlights these concerns and
has informed important research on developmental trajectories in ASD.
Current State of Clinical Treatment.
Pharmacological.
Medical intervention for individuals with ASD involves the use of prescription
medication. Two of the most commonly prescribed medications for ASD are risperidone and
aripiprazole. Both are atypical antipsychotic medications that are used to treat irritability in
children with ASD and have been shown to be effective in this treatment (Aman et al., 2015;
Maloney, Mick, & Frazier, 2014). A comparison of the studies supporting the use of these
medications found similar effectiveness between aripiprazole and risperidone, with each
possessing similar secondary effects such as weight gain, sedation and extra pyramidal syndrome
(Cohen et al., 2013). New medications, such as arbaclofen, are currently being researched as
alternative treatments for aggression in individuals with ASD that may avoid unwanted
secondary effects (Erickson et al., 2014).
Oxytocin is being researched as a possible medication for the treatment of core symptoms
of ASD, as opposed to treating aggressive behavior like atypical antipsychotics. While there is
some evidence that risperidone can improve the social functioning in children with ASD, this is
likely a result of the primary effect of this drug decreasing aggressive behaviors (Aman et al.,
2015). Oxytocin was initially considered as a possible treatment for ASD due to the role it
played in modulating similar symptoms in animal models (Stohn et al., 2018; Štefánik, Olexová,
& Kršková, 2015). While Oxytocin appears to have fewer secondary effects compared to
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atypical antipsychotics, the current research does not demonstrate meaningful effectiveness for
the core symptoms of ASD (Cai, Feng, & Yap, 2018; Keech, Crowe, & Hocking, 2018)
While atypical antipsychotic medications are effective in treating aggressive symptoms
and irritability in individuals diagnosed with ASD, they occur with serious secondary effects,
and are not effective at treating the core symptoms of ASD. Oxytocin has been proposed as a
possible treatment for the core symptoms of ASD, but research has yet to demonstrate this
effectiveness. There are also no known cures for the ASD (Bölte, 2014). In the absence of
effective pharmacological interventions, behavioral treatment has become the primary method
for improving outcomes of individuals with ASD.
Applied Behavioral Analysis.
The first treatment to consider when looking at interventions for ASD is Applied
Behavioral Analysis (ABA). This treatment is considered the first-line therapy for ASD and is
the most empirically validated treatment program for ASD (Magiati, Tay, & Howlin, 2012;
Munshi et al., 2011). ABA therapy was developed through the 1970’s and 80’s by Dr. Lovaas
and was originally described as the “Lovaas Method” (Dillenburger & Keenan, 2009; Lovaas,
1987). This treatment method evolved out of B.F. Skinner’s work on behaviorism and proceeds
by controlling the client’s environment in order to elicit desired behavior. This treatment follows
the stimulus-response model of human behavior and shapes patient’s behaviors by imposing a
system of reward and punishment for desired and undesired behaviors (Bondy, Esch, &
Sundberg, 2010).
ABA treatment is developed according to an individual needs assessment. The
behavioral needs assessment is traditionally done by administering a behavioral instrument such
as the Verbal Behavior Milestones Assessment and Placement Plan (VB-MAPP) which indicates
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the level of functional behavior of patients (Sundberg, 2008). This assessment provides a
template from which therapists develop the initial behavior plan, which targets specific behaviors
for increase or decrease, and outlines the intervention protocols for each behavioral goal.
Specific behavior goals can range – from a child remaining seated for a period of time, to
answering WH questions (who, what, where and when) effectively, to decreasing self-injurious
behavior. The protocols for achieving each goal can vary, but the most common is Discrete Trial
Training (DTT), which consists of presenting a patient with a specific task and rewarding
appropriate behavior (Magiati, Tay & Howlin, 2012). Rewards are labeled “reinforcers” since
ideally, they reinforce preferred behaviors. As ABA therapy progresses, goals are revised
depending on the progress of an individual patient. Behavioral data is taken over a series of
sessions and informs a behavioral therapist’s judgment regarding the need to adjust goals or
treatment protocols.
Reliance on DTT has waned in recent years as new methods of ABA have been
developed. Pivotal Response Treatment (PRT) and Early Start Denver Model (ESDM) are two
methods of behavioral treatment which rely on identifying goals for children and using
behavioral reinforcement techniques to achieve those goals. PRT is distinguished from DTT
because goals are areas of development, such as motivation and social initiation, as opposed to
discrete behaviors (Duifhuis et al., 2017). Research has demonstrated the effectiveness of PRT in
improving functioning for children with ASD in the domains of socialization, communication,
and daily living skills (Ventola et al., 2014; Ventola et al., 2016; Duifhuis et al., 2017). As with
all forms of ABA, however, responsiveness to PRT is not consistent across all participants and
researchers are looking for markers that might identify those who are less responsive to
intervention (Fossum, Williams, Garon, Bryson, & Smith, 2018). Research into this modality has
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incorporated neural measurements which may help identify treatment resistant subrgoups of
ASD (Ventola et al., 2015).
ESDM involves more parent participation than other ABA methods and allows therapists
to work on developing interpersonal relationships with their clients (Ryberg, 2015). The
effectiveness of this approach has provided practitioners with another viable method for treating
ASD (Dawson et al., 2010). Most noteworthy about the ESDM approach, however, is that is
demonstrated the importance of timing and intensity of behavioral intervention. Behavioral
treatment of children with ASD is most effective when it is intensive, at least 20 hours of
intervention a week, and delivered as early as possible, even for children as young as 12 months
of age (Rogers et al., 2012). Benefits of early and intense intervention have been replicated with
other ABA techniques and is not restricted to ESDM (Elder, Kreider, Brasher, & Ansell, 2017).
The importance of early intervention has impacted clinical approaches to diagnosis, since better
outcomes are associated with earlier treatment, clinicians have started to provide effective
methods for early diagnosis (Vietze & Lax, 2018). The Autism Diagnostic and Observation
Schedule was revised in 2012 to include a new toddler module, which allows for the earlier
detection of ASD, even among children as young as twelve months of age.
Treatment Outcomes and Effectiveness.
Quality of life for individuals diagnosed with ASD is significantly lower than their
typically developing counterparts (van Heijst & Geurts, 2015), and the majority of children
receiving the diagnosis will likely require lifelong care (Billstedt, Gillberg & Gillberg, 2005). In
one of the largest samplings to explore the question of outcomes for individuals with ASD,
researchers found that 58% of participants had ‘Poor’ or ‘Very Poor’ outcomes in terms of
employment, independent living, friendships, and language ability (Howlin, Goode, Hutton, &
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Rutter, 2004). Poor outcomes were most strongly correlated with low verbal IQ (<70) even
though participants with verbal IQ’s below 50 were excluded from this study. These outcomes
appear to be the result of variable responses to treatment, rather than a necessary outcome of the
disorder.
Although intense, early intervention ABA is the most empirically validated treatment for
ASD (Peters-Scheffer et al., 2011) portions of the population continue to respond less favorably
than others (Eikeseth, 2009). This variable responsiveness has led researchers to look for patient
factors that may predict outcomes of behavioral intervention. While researchers continue to
examine behavioral profiles to answer this question, two factors have achieved consensus in
terms of their impact on treatment responsiveness, namely, verbal IQ and early intervention
(Peters-Scheffer et al., 2011). Access to early and intensive behavioral intervention has been
shown to be a necessary condition for positive outcomes in individuals with ASD, and these
findings have influenced social policy to increase provision of these services to families. The
impact of verbal IQ on treatment outcomes has been more problematic, particularly because this
feature is difficult to measure in young children receiving early and intensive behavioral
intervention.
Developmental trajectories which incorporate clinical considerations have also
highlighted the importance of verbal IQ when identifying outcomes in adults with ASD. The first
study of this kind used longitudinal data to show that outcomes at age 19 of children diagnosed
with ASD was strongly predicted by verbal IQ at age 2 or 3. In particular, individuals with verbal
IQs below 70 were found to have poor outcomes in 85% of cases (Anderson, Liang, & Lord,
2014). Additional research using similar methods has replicated these findings, showing that
grouping individuals with ASD into low and average IQ groups, based upon a verbal IQ
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benchmark of 70, strongly predicts outcomes in later life (Lord, Bishop, & Anderson, 2015).
These findings were also replicated in a study with a dividing point of verbal IQ at 85 (Kim, Bal,
& Lord, 2018). These crucial findings provide a starting point for researchers interested in
identifying early biomarkers that could detect treatment resistant subgroups of ASD.
Purpose of this Study
The purpose of our study is to investigate a potential biomarker that could distinguish
individuals with autism and low verbal IQ from their average verbal IQ, and typically
developing, counterparts. The analysis we propose attempts to distinguish these groups within a
sample of children age four to eleven-years-old, when IQ is considered more stable and measures
of verbal IQ are more reliable. The utility of this biomarker, however, would ultimately be found
in its application to distinguish these groups in toddlerhood, when treatments are first introduced
and there is a need for early identification of treatment resistant subgroups. For this reason, we
have chosen a biomarker which has demonstrated its effectiveness at identifying ASD among
toddlers.
Bosl et al. (2011) demonstrated that sample entropy analysis of resting state EEG signals
could effectively distinguish a group of children at high risk for autism, due to a sibling
diagnosis, and healthy controls. Participants in the study were between 6 and 24 months old, with
the most significant findings for children between 9 and 12 months of age. Sample entropy
measurements have the potential to aid in early diagnosis of ASD as indicated by Bosl et al.
(2011). However, the most pressing clinical need for this population is the early detection of
individuals who do not respond as well to behavioral intervention and have worse outcomes in
adolescence and adulthood. The purpose of our study is to examine whether sample entropy is
able to identify this group in a sample of children between the ages of four and eleven.
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Research Questions
The analysis presented in our study proceeds in two parts. The initial analysis sheds light
on the sample by examining the cognitive profiles of participants, and the relationship between
demographic factors, such as sex and age, with scores on behavioral measures. The second phase
of the analysis introduces sample entropy, and this is where our research questions are posed.
Our first research question – is sample entropy correlated with measures of ASD symptoms, IQ,
and adaptive functioning? – is addressed in a correlational analysis between sample entropy
measurements and scores on the ADOS-2, DAS-II, and Vineland-II. Our second research
question – can sample entropy distinguish Typ, ASDAvg, and ASDLow groups? – is addressed
through an ANOVA analysis of sample entropy measurements between these groups. Additional
considerations addressed by our research are covered in the “Discussion” section of this paper,
however, the above are our two primary research questions.
Relevance of this Study
The relevance of this study comes from the introduction of biological measures to
improve our understanding of ASD. Research into the biological underpinnings of ASD is part of
a broader movement to define disorders through physiological measurements, embodied most
concretely in the RDoC project (Insel, et al., 2010). Our research builds on previous research by
Bosl, et al., (2011), which has demonstrated that sample entropy is effective at distinguishing
children at high risk of ASD from typically developing counterparts. It could be argued that the
relevance of our study is derived from the extension of this method is an attempt to broaden our
understanding of ASD from a biological perspective.
More importantly, however, this study uses biological measures to address a pressing
clinical need in the field of ASD research. The goal of this study is to use the method of sample
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entropy analysis identified in Bosl, et al. (2011) to distinguish low verbal individuals with ASD
from their high verbal, and typically developing, counterparts. If this method has the ability to
distinguish these groups, then it is possible that clinicians could identify treatment resistant ASD
in infancy. This would allow clinicians and researchers to develop and test alternative treatments
with the goal of improving outcomes for those with the highest need on the autism spectrum. If
our study shows promise, then sample entropy would be a worthwhile measure to incorporate
into longitudinal studies on ASD, to improve our understanding of biological measures in the
context of change over time.
Defining Entropy
Entropy has different definitions depending on the discipline in which it used, most
notably thermodynamics and information theory. The use of entropy, or sample entropy, in our
study is more closely aligned with the definition of the term used in information theory. Here,
entropy was first defined by Claude Shannon in a paper titled A Mathematical Theory of
Communication (1948). Entropy in information theory is defined as a measure of uncertainty
determined by the probability of possible outcomes. Under this definition, the outcome of a dice
roll has greater entropy than the flip of a coin, since the dice roll resolves uncertainty related to
six possible outcomes and the coin flip resolves uncertainty related to two possible outcomes.
One of the earliest applications of entropy in describing a sequence of events occurred in
Claude Shannon’s living room with his wife, Betty. They observed together that, when provided
the first few words of a sentence in English, subsequent words became easier and easier to guess.
That is to say, the uncertainty of guessing possible words early in a sentence in English is greater
than the uncertainty of guessing words later in that same sentence (Horgan, 2016). Information
theory has transformed the observations made in the Shannon’s living room into a science which
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characterizes the nature of information in communication systems such as English, as well as
those found in the natural world.
Costa, Goldberger, and Peng (2005) applied information theory and the concept of
entropy to biological signals, looking specifically at cardiac rhythms. These researchers found
that the complexity of biological signals generated by the heart were an indicator of advanced
age, atrial fibrillation, and congestive heart failure. Complexity in this study was measured by
multiscale entropy, which analyzed time series data generated by cardiac rhythms and examined
how frequently pairs of data points were replicated in the remaining sequence. Signals which
were highly ordered and regular, where pairs of data points were replicated frequently
constituted a signal with less complexity and lower entropy. These patterns were more
commonly associated with pathological heart conditions. In contrast, signals that were less
regular were associated with healthier heart conditions. Considered from the perspective of
entropy, the more regular cardiac rhythms can be said to contain less uncertainty because data
later in the sequence can be more accurately predicted based upon data early in the sequence.
Signals with more complexity have higher entropy because there is greater uncertainty about the
position of data later in the sequence, based upon knowledge of data early in the sequence.
Bosl et al. (2011) applied the method developed by Costa, Goldberger, and Peng (2005)
to EEG signals in order to distinguish a group of children at high risk of ASD from typically
developing peers. This method is the basis of our study. Other researchers have used measures of
entropy in neuroscience, most notably identifying entropy within fMRI data as a possible
indicator of intelligence (Saxe, Calderone, & Morales, 2018). The use of sample entropy to
identify a subgroup of ASD with low verbal ability, as proposed in our study, is part of an
expanding use of entropy within the neuroscience research community.

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

20

Methods
Research Design
The data for our study was retrieved from the National Database for Autism Research
(NDAR), which is an NIMH Data Archive. This data archive serves as a repository for deidentified, research participant data made available to the wider research community.
Researchers can access participant data based upon search parameters, which return appropriate
collections of client data. This is a useful mechanism for researchers interested in meta-analytic
studies because it does not impede cross-study comparisons. For our purposes, however, it was
necessary to find a single study with the relevant participant data, because a small sample was
more suited to the pilot study we were pursuing.
A preliminary review of research in NDAR generated five candidate studies which had
collected data appropriate for our research. The data required for our study was, EEG
measurements, IQ tests (either WAIS or DAS), ADOS scores, and Vineland scores. Five studies
had performed research which included this data. Ultimately, we selected the Autism Biomarkers
Consortium for Clinical Trials (NDAR #2288) as our data source because it had the appropriate
number of participants (51), the subject records were largely complete (forty-nine of the fifty-one
participants had EEG, IQ, ADOS, and Vineland data), and EEG data was the appropriate length
(resting state measurements were about one minute long). There were also multiple resting state
EEG measurements in case of bad electrodes or eye movement artifacts. This study collected
three resting state measurements taken on two visits, for a total of six possible data points. EEG
data files were also in Matlab format, which was conducive to our proposed analysis.
The Autism Biomarkers Consortium for Clinical Trials is an investigation led by James
McPartland at Yale University and its principle aim is to collect EEG, eye tracking(ET),
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intelligence, and social impairment data to identify biomarkers which may help stratify the
currently heterogeneous category known as ASD into subgroups. Assessments in this study were
conducted at three timepoints, including baseline, 6 weeks and 24 weeks. The ADOS-2, DAS-II
and Vineland-II were only administered at baseline, but EEG, ET and social impairment
measures were administered at all time points. Participant data was made available through
NDAR with the help of the Data Acquisition and Analysis Core. The rationale and methodology
of the study is outlined in McPartland (2017).
Participants
This Autism Biomarkers Consortium for Clinical Trials recruited typically developing
children and children diagnosed with ASD between 4 and 11 years of age. Participants were
recruited at five sites throughout the Unites States – Boston Children’s Hospital, Duke
University, UCLA, University of Washington, and Yale Child Study Center. While enrollment in
this study is ongoing, at the time of our analysis there were fifty-one participants with data
available through NDAR. Participant demographics and cognitive profiles are considered in
more detail at the beginning of the “Results” section.
Procedures
For our research, data from NDAR study #2288 was accessed, downloaded, and cleaned
using Matlab code. The data tables provided by NDAR contained numerous redundancies and
omissions when initially accessed. Redundancies were eliminated and omissions were
standardized in the cleaning of this data. Relevant scores from the ADOS-2, DAS-II, and
Vineland-II were organized by participant for our analysis. Participant groups were divided by
diagnostic categories and verified using ADOS-2 comparison scores. Participant groups were
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further refined by identifying a “Low Verbal” subgroup of children diagnosed with ASD who
had verbal IQ scores below 85.
The Autism Biomarkers Consortium for Clinical Trials collected EEG data using a
Clinical Geodesic EEG System 400 with 128 electrodes. A map of electrode locations for this
system is included in Appendix A. For our analysis of sample entropy, fewer electrode sites were
required and we selected the most commonly used 19 sites, including C3, C4, O1, O2, Cz (Ref in
Appendix A), F3, F4, F7, F8, Fz, Fp1, Fp2, P3, P4, P7, P8, Pz, T7, T8. The 1000 Hz sampling
rate of the Clinical Geodesic EEG System 400 allowed for an analysis of sample entropy at six
frequencies, High Gamma, Gamma, Beta, Alpha, Theta, Delta.
Sample entropy was calculated within these frequencies at each of the nineteen scalp
locations recorded for participants, resulting in one hundred and fourteen sample entropy
measurements per participant. This method of identifying sample entropy was first identified by
Costa, Goldberg, and Peng (2014), and can be applied to any physiological data represented as a
time series, traditionally EEG and EKG data. This method for determining sample entropy has
been adapted and modified by subsequent researchers, most notably in the study distinguishing
typically developing infants from those at high risk of ASD. The sample entropy measurements
for our study follows the method developed in this study. (Bosl, et al., 2011)
Measures
The behavioral measures selected for our study are the ADOS-2, DAS-II, and VinelandII. The ADOS-2 comparison score was used to confirm ASD diagnosis and distinguish the
control group and children diagnosed with ASD. The DAS-II was used to identify children with
verbal IQ scores lower than 85. Additional scores provided by the ADOS-2 and DAS-II were
included in our initial analysis to present a complete picture of the sample. The Vineland-II was
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also included to present adaptive behavior profiles of participants, and ensure that the expected
correlations between ASD severity, IQ scores, and adaptive functioning were intact for this
sample. Below is a summary of the three measures used.
ADOS-2.
The ADOS-2 is an assessment instrument used for the diagnosis of ASD. It consists of
standard activities for clients which allow the assessor to observe behaviors relevant to ASD
diagnosis (Lord, et al., 2012). Many of the activities used in the ADOS are planned social
activities designed specifically to create a context where the communicative and social
impairments of ASD become apparent. The assessment may be administered to anyone over 12
months of age and there are five modules for clinicians to select between. Each module contains
a list of activities designed for different ages and verbal ability. The toddler module can be
administered to children between 12 and 30 months of age. It consists of simple social
interaction that does not require verbal ability, such as passing a ball back and forth with the
assessor and presents the child with cause-and-effect toys which often elicit restricted and
repetitive behavior. Modules 1-4 present activities appropriate for older children and adults.
Module 4 consists largely of conversation where the assessor asks the client to discuss topics
such as friendship, emotional attunement, and social difficulties, among others. Tactile activities,
such as a spinning disk, are also presented to explore potential repetitive and restrictive behavior.
Each module of the ADOS-2 is scored in a similar fashion. The assessor takes careful
observational notes during the assessment and provides the client with a score between 0-3 in a
number of domains. Zeros are given for typical behavior, and threes for behavior consistent with
ASD. For example, in Module 4 domain A10, Emphatic or Emotional Gestures a 0 is given when
a client exhibits “a range of appropriate emphatic and/or emotional gestures that are well
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integrated with speech,” and a 3 is given when there is “no or very limited emphatic or emotional
gestures.” (Lord, et al., 2012) The algorithm for diagnosis selects those domains which
distinguished typically developing children from children with ASD in the validation sample. A
sum of scores in these domains is converted to a comparison score between 1 and 10. The
modules are aligned so that a comparison score of 4 in any module is considered consistent with
a diagnosis of ASD.
The ADOS-2 can be administered by clinical psychologists and physicians with prior
education, training, or experience with the instrument. (Lord, et al., 2012) The Autism
Biomarkers Consortium for Clinical Trials administered the ADOS-2 for every client and the
scores are considered valid for our purposes. Participants in our study were distinguished into
typically developing and ASD groups by clinical diagnosis, and each participant was verified as
having an ADOS-2 comparison score of 4 or greater.
Validity and reliability for the ADOS-2 built upon previous studies of the original ADOS
since many of the items and administration remained the same. The ADOS-2 extended validation
sample contained 1,415 individuals and 2,195 assessments. While the toddler module was
introduced in the ADOS-2, our study only relied on administration of modules 1, 2, and 3.
Interrater reliability of items within the validation sample had an exact reliability of 91.5%, 89%,
and 88.2% for modules 1, 2, and 3 respectively. Test-retest reliability was .87, .83, and .87 for
module 1, 2, and 3 over the course of 10 months, with much of this change attributed to the
effects of behavioral intervention. Item validity and their correlation with ASD diagnosis
remained largely consistent between the ADOS and ADOS-2, however, new diagnostic
algorithms were developed to increase sensitivity of the instrument to the verbal ability of
children. For example, module 1 contains two algorithms for children based on their ability to
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produce five or more words during the assessment. Children able to produce more words receive
higher Comparison scores based on fewer symptoms, because children with lower language
abilities naturally produce more autistic-like symptoms to facilitate their social communication.
Additional items that do not factor into diagnostic scores, such as “Anxiety” and “Overactivity”,
are included in the assessment, because they can influence behavior observation during the
assessment.
DAS-II.
The DAS-II is composed of cognitive batteries that measure verbal ability, nonverbal
reasoning, and spatial ability. The Early Years battery can be administered to children between
the ages of two and a half and six years eleven months. The School-Age battery can be
administered to children between seven and eighteen years of age. The division of batteries
allows for flexibility in administration so that older children with lower ability may be
administered the Early Years battery, while younger children with greater ability may be given
the School Age battery (Elliott, 2007).
The DAS-II General Conceptual Ability (GCA) score is derived from the three cluster
scores – verbal, nonverbal, and spatial ability – and is a measure of psychometric g, often
referred to as intelligence or IQ. The author of the DAS-II, however, finds the labels
“intelligence” and “IQ” problematic, and stresses the value of cluster scores over the GCA. Each
cluster is a homogeneous assessment of a particular component of g, with verbal ability
measuring crystallized intelligence, nonverbal reasoning measuring fluid reasoning, and spatial
ability measuring visual processing and visual-spatial ability. (Elliott, 2007) Therefore,
interpretation of cluster scores, and their differences, provides a more nuanced picture of a
child’s cognitive profile when compared to the single GCA score. While the Autism Biomarkers
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Consortium for Clinical Trials uses the DAS-II as a measure of intelligence, and the term “IQ” is
commonly used in the literature we reviewed, our individual analysis is more in line with the
method of interpretation advocated by the author of the DAS-II, since we rely on the Verbal
Ability score rather than the GCA to differentiate participant groups.
Like the ADOS-2, the DAS-II is the second iteration of an established psychometric
assessment and builds upon its predecessor to establish reliability and validity. Intercorrelations
between subtests of the DAS-II support the conclusion that distinct, but related abilities, are
measured by the instrument. Factor analysis of DAS-II scores indicated that the number of
cognitive abilities measured by this instrument increased with age, consistent with findings in the
original DAS sample. This development supported the division of the DAS-II into the Early
Years and School Age subtest. External validity of the DAS-II was established through a
comparison with other measures, most notably the Wechsler Intelligence Scale for Children,
Fourth Edition, with correlations between GCA-Full scale IQ, Verbal Ability-VCI, and SNC-PRI
being .84, .73, and .77 respectively.
Vineland-II.
The Vineland-II is a measure of adaptive functioning commonly used to assess an
individual’s ability to manage the practical requirements of daily life. It measures functioning in
the domains of Communication, Daily Living Skills, and Socialization. The Communication
domain assesses receptive, expressive and written language skills, Daily Living Skills assesses
personal, domestic, and community skills, and Socialization measures interpersonal relationship,
play and leisure, and coping skills. (Sparrow, Cicchetti, & Balla, 2005) The domain scores are
combined to provide an Adaptive Behavior Composite score, which estimates overall adaptive
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functioning. Additional domains assessing motor skills and maladaptive behaviors can also be
administered.
The Vineland-II is frequently used as a measure of adaptive functioning for children with
ASD. Adaptive functioning is a particularly useful area for assessment because it identifies
barriers individuals may encounter as they work towards independent living. Along with
diagnostic instruments such as the ADOS-2, and IQ measurements such as the DAS-II, the
Vineland-II is administered to individuals with ASD to provide a more complete picture of their
behavioral profile. When new instruments are developed for assessing individuals with ASD, the
Vineland-II is often included to demonstrate correlations between established measures and the
proposed instrument (Craig et al., 2017).
The Autism Bioarkers Consortium for Clinical Trials provided results of the Vineland-II
assessment for all participants in the NDAR database. The adaptive profiles of participants
included the three domains scores as well as the Adaptive Behavior Composite. Our study
included Vineland-II scores to generate a more complete picture of participants behavioral
profile.
Data Analysis Plan
The data collected for our study was processed according to the Matlab code presented in
Appendix A. The first step in the research process was to import the data from NDAR, clean the
data, standardize values, organize data across measures by participant, and separate participants
into typically developing (Typ), ASD with average verbal ability (ASDAvg), and ASD with low
verbal ability (ASDLow) groups. While the more common point of division between average and
low verbal ability is a verbal IQ of 70, two standard deviations below the norm (Lord, Bishop, &
Anderson, 2015; Anderson, Liang, & Lord, 2014), our sample contained only two participants in
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the lower category using this metric. To remedy this problem, we used a dividing score of verbal
IQ 85, one standard deviation below the norm, which raised our participant number in this group
to eight. This method of grouping has also been used in studies which identified low functioning
subgroups of ASD (Kim, Bal, & Lord, 2018).
The second step involved an analysis to determine the cognitive profiles and
demographic features of the sample, looking specifically at the effects of sex and age on the
sample. The third step was a correlational analysis examining the relationship between
behavioral measure scores, including the ADOS-2, DAS-II, and Vineland-II. The fourth step
included participant’s sample entropy measurements and examined the correlation between
sample entropy and scores on behavioral measures. The fifth and final step was an ANOVA
analysis which attempted to distinguish Typ, ASDAvg, and ASDLow groups using only sample
entropy measurements.
Results
Initial Analysis
The psychological scores of subjects in this study indicate a wide range of abilities in
adaptive functioning, levels of intelligence and presence of autistic symptomatology. Table 1
presents a summary of the scores for scales and subscales on the ADOS-2, DAS-II and VinelandII. These scores depict the wide variety of cognitive profiles present in the current sample.
Verbal intelligence, for instance, ranges from the very high at 148 to very low at 30. The ADOS2 Comparison scores range from 0, suggesting no autistic symptomatology to 10, the highest
possible score on this measure. The Vineland-II Communication subdomain scores span from the
Low range at 42 to the High range at 130. These scores indicate that a variety of cognitive
abilities occur within this sample and suggest that, although the sample size is limited, it has

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

29

captured the diverse cognitive presentations in the wider population of typically developing
children and children diagnosed with ASD.
Table 1
Summary of Subject Age Distribution and Assessment Scores
Row
Min Max Mean
Standard_Deviation
Age
49 138 87.81632653
26.5021017
ADOS_SA
0 17 5.897959184
5.792397668
ADOS_RRB
0
8 1.734693878
2.233975438
7.460154929
ADOS_Total
0 23 7.632653061
ADOS_Comparison
1 10 4.265306122
3.480753691
30 148 104.4081633
IQ_Verbal
21.03560312
14.99040769
IQ_Nonverbal
55 133 105.6041667
101
16.23890783
IQ_Spatial
46 136
IQ_GCA
42 133 104.9787234
18.2178715
IQ_SNC
42 124 104.1041667
15.28069229
Vineland_Comm
42 130 95.44897959
21.93746911
Vineland_DLS
45 121 90.08163265
17.22018769
Vineland_Soc
57 118 90.28571429
18.41760933

Within the sample we found that there are strong correlations between domains of
intelligence, adaptive functioning and autistic symptomatology. Correlations between subscales
of individual measures are to be expected and reflect the internal consistency of well-developed
psychological testing instruments. The correlations between measures, however, indicate that
abilities were consistent across domains. For example, in our sample, strengths in intelligence
were correlated with higher levels of adaptive functioning and lower levels of autistic
symptomatology, while higher levels of autistic symptomatology were correlated with lower
adaptive functioning and IQ scores. A full correlational analysis between subscales of the
psychological measures are provided below in Table 2. For each correlation coefficient listed
there is a related p-value below .05, with blank cells having nonsignificant correlations.

Table 2

Summary of Correlations Between Assessment Scores
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ADOS_SA ADOS_RRB ADOS_Total ADOS_Comparison IQ_Verbal IQ_Nonverbal IQ_Spatial IQ_GCA IQ_SNC Vineland_Comm Vineland_DLS Vineland_Soc Age
Row
ADOS_SA
1 0.661178383 0.974437395 0.947874968 -0.584590959 -0.435728125 -0.645030726 -0.65976221 -0.632331218 -0.777906986 -0.676632428 -0.778709749 0.339156792
1 0.812822739 0.764778326 -0.51952817 -0.305920964 -0.413714719 -0.494210928 -0.424126821 -0.616043193 -0.527982869 -0.629532355
ADOS_RRB
0
1 0.964988639 -0.612029457 -0.431621484 -0.627125547 -0.66290604 -0.620383304 -0.788478528 -0.683474393 -0.793141216 0.308711525
ADOS_Total
0
0
0
0
1 -0.534940322 -0.356765322 -0.547858056 -0.583065693 -0.527965942 -0.764982798 -0.637472448 -0.779526234 0.380405887
ADOS_Comparison
0
0
0
0
1 0.612382413 0.667240465 0.920715132 0.753693428 0.644506746 0.572792993 0.536673003
IQ_Verbal
0
1 0.454779814 0.779777763 0.836013695 0.399791667 0.354620133 0.345235535
0
0
0
0
0
IQ_Nonverbal
0
0
0
0
0
1 0.829612335 0.867553906 0.700990542 0.733379266 0.601395476
IQ_Spatial
0
0
0
0
1 0.944927347 0.696429523 0.65339078 0.590381706
0
0
0
IQ_GCA
0
0
0
1 0.653530352 0.648792962 0.559577108
IQ_SNC
0
0
0
0
0
0
1 0.859226181 0.860934278
0
0
0
0
0
0
Vineland_Comm
0
0
0
Vineland_DLS
0
0
0
0
0
0
0
0
0
0
1 0.864776295
0
1
Vineland_Soc
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
Age
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The strongest correlations occur between subscales of the same measure, as we might
expect. There are some interesting correlations between measure subscales, most notably the
ADOS-2 subscales and Vineland-II subscales. Total ADOS-2 scores are correlated with the
Vineland-II Communication and Socialization scores at -.78 and -.79 respectively. DAS-II
subscale correlations are more modest, with the Verbal, Nonverbal, Spatial and GCA correlated
with ADOS Total scores at -.61, -.43, -.62 and -.66 respectively. These correlations are intuitive
since the adaptive functioning scales of communication and socialization measure behavior more
closely aligned with the core features of ASD, in contrast to intelligence measures.
An additional noteworthy feature of Table 2 is the age column and its correlational
coefficients. This column was included because, unlike Sex which is binary, age is a continuous
measurement which can be easily compared to a range of scores provided by psychological
measurements. In Table 2, age has a correlation of .33, .30 and .38 with the Social Affect, Total
and Comparison scores of the ADOS-2, respectively. These correlations are important because
they explain the significant difference in age we find between our sample subgroups, described
below. The significant relationship between age and autistic symptoms in our sample presents a
possible confound in our final analysis, and is important to keep in mind.
When we divide our sample into three groups, Typ, ASDAvg, and ASDLow we find
significant differences in group performance across measures. Tables 3, 4 and 5 provide t-test
comparisons between Typ-ASDAvg, Typ-ASDLow and ASDAvg-ASDLow respectively. We
consider each comparison in turn.
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Table 3
Summary of T-Tests Between Typically Developing Children, and Children with ASD and
Average Verbal IQ
Row
T_test
p_value
Typ Mean
Typ Stand_Dev ASDAvg Mean ASDAvg Stand_Dev
Age
1 0.009492594
79.84615385
23.93272623
101.3125
26.16287127
ADOS_SA
1
2.69482E-14
1.153846154
1.222859197
10.625
3.913651322
ADOS_RRB
1
6.75654E-07
0.192307692
0.491465626
3
2.366431913
ADOS_Total
1
4.92593E-17
1.346153846
1.354763675
13.625
4.145278439
ADOS_Comparison
1
1.97056E-21
1.192307692
0.401918476
7.6875
1.701714821
IQ_Verbal
1 0.004574464
115.2307692
13.79364402
102.125
13.61800279
IQ_Nonverbal
0 0.360184567
IQ_Spatial
1 0.005838726
108.7692308
10.69320417
97.9375
13.21851605
IQ_GCA
1 0.002452185
114.0769231
9.337764516
103.8
10.53700961
IQ_SNC
1 0.008059528
111.0384615
8.032338485
102.875
10.89877669
Vineland_Comm
1
1.55032E-08
111.2692308
14.27041048
80.9375
12.1735711
Vineland_DLS
1
9.59943E-05
100.3461538
13.95691171
82.75
10.5229907
Vineland_Soc
1
9.51556E-09
103.5769231
12.1759536
76.125
11.64402565
Sex
0 0.119002227

Table 3 reviews the results of t-tests comparing psychological scores of the Typ group
compared with the ASDAvg group. The pervasive differences across virtually every domain is
striking. While differences in ADOS scores are predictable, what is interesting about this
comparison is that the ASDAvg group has, in some ways, controlled for intelligence by
removing those subjects with low verbal IQ. Nevertheless, we find that there remain significant
differences in all domains of intelligence apart from nonverbal IQ. This may be due to the
elevated IQ scores of the Typ group as we see in their mean GCA of 114. This is nearly a full
standard deviation higher than we would expect of a normal sample of typically developing
children. On the one hand, this presents challenges related to the generalizability of our study
and on the other hand it increases differentiation in performance between groups based on the
metric we hope to quantify through EEG sample entropy. These considerations will be explored
more fully in the discussion section of this paper.
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Table 4
Summary of T-Tests Between Typically Developing Children, and Children with ASD and Low
Verbal IQ
Row
T_test
p_value
Typ Mean
Typ Stand_Dev ASDLow Mean ASDLow Stand_Dev
Age
0
0.526767
ADOS_SA
1
3.87467E-15
1.153846154
1.222859197 12.71428571
3.545621042
ADOS_RRB
1
4.73035E-17
0.192307692
0.491465626 4.571428571
0.975900073
ADOS_Total
1
6.51288E-17
1.346153846
1.354763675 17.28571429
4.34796066
ADOS_Comparison
1
8.28383E-21
1.192307692
0.401918476 7.857142857
1.345185418
IQ_Verbal
1
3.41376E-08
115.2307692
13.79364402 69.42857143
18.29259543
IQ_Nonverbal
1 0.000136451
110
11.65160933
84
18.86796226
IQ_Spatial
1
7.06561E-07
108.7692308
10.69320417
75.5
16.08415369
IQ_GCA
1
2.76346E-10
114.0769231
9.337764516
68.5
16.58613879
IQ_SNC
1
1.62968E-07
111.0384615
8.032338485 77.33333333
20.02664891
Vineland_Comm
1
1.44043E-07
111.2692308
14.27041048 69.85714286
14.85966096
Vineland_DLS
1
6.05433E-06
100.3461538
13.95691171 68.71428571
12.29788987
Vineland_Soc
1
1.39492E-06
103.5769231
12.1759536 73.28571429
10.93487213
Sex
0 0.698519558

The results displayed in Table 4 are largely consistent with those displayed in Table 3. As
we would expect, the differences between Typ and ASDLow are more significant than those
between Typ and ASDAvg, which now includes nonverbal IQ. What is interesting to note about
these two groups is the absence of any significant difference based upon age. As opposed to the
Typ-ASDAvg comparison which did yield a significant difference based on age, the TypASDLow groups are not significantly different by age. This further analysis suggests that the
correlation between ADOS scores and age observed in Table 2 may be explained by the
disproportionately high age of the the ASDAvg group. As with the unusual IQ scores among the
Typ group discussed above, the differences in age within our sample poses some challenges with
the full analysis, which we discuss more fully below.
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Table 5
Summary of T-Tests Between Children with ASD and Average Verbal IQ, and Children with ASD
and Low Verbal IQ
Row
T_test
p_value
ASDAvg Mean ASDAvg Stand_Dev ASDLow Mean ASDLow Stand_Dev
Age
0 0.234278766
ADOS_SA
0 0.239943281
ADOS_RRB
0 0.108224763
ADOS_Total
0 0.068351606
ADOS_Comparison
0
0.81815885
IQ_Verbal
1 0.000101497
102.125
13.61800279 69.42857143
18.29259543
IQ_Nonverbal
1
0.00286087
106.5625
11.74716278
84
18.86796226
IQ_Spatial
1 0.003186254
97.9375
13.21851605
75.5
16.08415369
IQ_GCA
1
1.14746E-05
103.8
10.53700961
68.5
16.58613879
IQ_SNC
1 0.000937043
102.875
10.89877669 77.33333333
20.02664891
Vineland_Comm
0 0.073886234
Vineland_DLS
1 0.010714545
82.75
10.5229907 68.71428571
12.29788987
Vineland_Soc
0 0.589875197
Sex
0 0.113958894

Table 5 presents a comparison of psychological scores between the ASDAvg and
ASDLow groupings. These t-tests are consistent with the broader analysis and demonstrate no
significant differences within ADOS scores, although the ADOS-2 total scores approach
significance. The ADOS Comparison scores, which can be used to determine ASD severity, are
not significantly different. The ASDAvg and ASDLow groups are significantly different on
every IQ scale, which is to be expected given that the ASDLow group was selected precisely for
their lower verbal intelligence. There are some differences in adaptive behavior between these
groups, particularly in the daily living skills domain. The communication domain is approaching
significance, while the socialization domain is not significantly different. This is also consistent
with our expectations, since the groups are separated by verbal IQ but not social deficits common
to ASD.
While the sample appears to have some unusual features related to the high IQ of the Typ
group and age across groups, the tables above demonstrate that there are no significant
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differences related to sex within the sample. Table 6 below provides a full analysis comparing
psychological scores between males and females on every measure. While differences in IQ and
age remain to be addressed as we continue our analysis, differences based on sex do not appear
to be a factor in this sample.
Table 6
Summary of Sex Differences by Age and Assessment Scores
Row
T_test p_value
0 0.827296779
Age
Sex
1
0
0 0.182528699
ADOS_SA
ADOS_RRB
0 0.646728537
ADOS_Total
0 0.24165425
ADOS_Comparison
0 0.216283066
Diagnosis
0 0.32956458
0 0.595916102
ADI_A
ADI_C
0 0.580348519
ADI_D
0 0.107494795
0 0.268538444
IQ_Verbal
IQ_Nonverbal
0 0.496495635
IQ_Spatial
0 0.589462648
IQ_GCA
0 0.246893575
0 0.466080784
IQ_SNC
0 0.376655932
Low_Verbal
0 0.067189902
Vineland_Comm
Vineland_DLS
0 0.165954578
Vineland_Soc
0 0.156217139
Final_Cats
0 0.807642463

Given the differences in age identified above, it is worthwhile to explore more deeply the
relationship between age and psychological scores within this sample. Tables 7, 8 and 9 below
present t-tests comparing three age groups within the sample, the youngest, middle and oldest
thirds of subjects. Table 7 indicates that there is no significant difference between the youngest
and middle third on any psychological measure collected in this sample. Table 8 indicates a
significant difference between the youngest and oldest group on the ADOS Comparison score,
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and table 9 indicates the same difference between the middle and oldest group. The differences
on the ADOS Comparison scores arise due to the significantly higher older group average, 6.125,
while the younger and middle group are 3.176 and 3.562 respectively. These differences help
explain the correlations between age and ADOS scores seen in table 2. Tables 7, 8, and 9 also
demonstrate that no significant differences are present between age groups in other domains
assessed.
Table 7
Comparison Between the Youngest and Middle Third of the Sample by Age, Sex, and Assessment
Scores
Row
T_test
p_value Young_Mean Young_SD Med_Mean Med_SD
Age
1 7.5E-10 59.58823529 7.38290952
86.125 9.97246208
Sex
0 0.109393
ADOS_SA
0 0.724838
ADOS_RRB
0 0.496628
ADOS_Total
0 0.939044
ADOS_Comparison
0 0.721563
IQ_Verbal
0 0.847627
IQ_Nonverbal
0 0.909224
IQ_Spatial
0 0.730877
IQ_GCA
0
0.5941
IQ_SNC
0 0.850829
Vineland_Comm
0 0.478065
Vineland_DLS
0 0.440804
Vineland_Soc
0 0.785106
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Table 8
Comparison Between the Youngest and Oldest Third of the Sample by Age, Sex, and Assessment
Scores
Row
T_test
p_value Young_Mean Young_SD Old_Mean Old_SD
Age
1 1.43E-18 59.58823529 7.38290952
119.5 10.6332811
Sex
0 0.618854
ADOS_SA
0 0.053486
ADOS_RRB
0 0.28587
ADOS_Total
0 0.066258
ADOS_Comparison
1 0.016018 3.176470588 2.94183816
6.125 3.6855574
IQ_Verbal
0 0.529656
IQ_Nonverbal
0 0.687872
IQ_Spatial
0 0.301457
IQ_GCA
0 0.539968
IQ_SNC
0 0.425117
Vineland_Comm
0 0.405948
Vineland_DLS
0 0.759921
Vineland_Soc
0 0.532245

Table 9
Comparison Between the Middle and Oldest Third of the Sample by Age, Sex, and Assessment
Scores
Row
T_test
p_value Med_Mean
Med_SD
Old_Mean Old_SD
Age
1 3.41E-10
86.125 9.97246208
119.5 10.6332811
Sex
0 0.278873
ADOS_SA
0 0.102874
ADOS_RRB
0 0.094053
ADOS_Total
0 0.073055
ADOS_Comparison
1 0.044891
3.5625 3.22425702
6.125 3.6855574
IQ_Verbal
0 0.566819
IQ_Nonverbal
0 0.75813
IQ_Spatial
0 0.108865
IQ_GCA
0 0.122058
IQ_SNC
0 0.20558
Vineland_Comm
0 0.137058
Vineland_DLS
0 0.238494
Vineland_Soc
0 0.381701
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This initial analysis summarizes the psychological scores within our sample and
compares these scores to demographic features of participants, namely age and sex. When
looking at psychological scores within the sample, they are strongly correlated with one another.
That means that higher performance in one domain is correlated with higher performance in
other domains, while lower performance is one domain is correlated in lower performance in
others. Age is not significantly correlated with any psychological score apart from ADOS-2
comparison scores, and there are no significant differences based on sex. When we compare Typ,
ASDAvg and ASDLow groups we find that, consistent with the correlational analysis, there are
many significant differences across domains between groups. As a result of the groups being
separated in part based on ADOS-2 comparison scores, age is significantly different between the
Typ and ASDAvg group. The perturbation of age within the sample appears to stem from the
unusually high ADOS-2 comparison scores among older participants. The second stage of our
analysis involves comparing psychological scores and subject groups with sample entropy
measurements.
Sample Entropy Analysis
The sample entropy analysis proceeds in two parts. First, we explore the correlation
between subjects’ psychological scores and sample entropy measurements. This analysis
includes subtests of the ADOS-2, DAS-II and Vineland-II measurements, as well as age. Sample
entropy is measured at 114 points for every participant, composed of six wavelength bands for
each of 19 scalp locations. The second, and final phase of the analysis, proceeds by comparing
the sample entropy between Typ, ASDAvg and ASDLow using ANOVA at each of the 114
measurement points.
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Of the 114 sample entropy calculations available to provide a significant correlation with
age or psychological scores, 25 measurements generated positive results. These are displayed
below in Table 10, which has been divided in two for ease of reference. Fifteen of 19 scalp
locations bore positive correlations with psychological scores, which are reported in the first row
of Table 10. Wavelength bands are reported in the second row and suggest that specific bands
are much more important for our analysis compared to others. The totals come to High Gamma
(0), Gamma (1), Beta (1), Alpha (12), Theta (5), Delta (6). This suggests that sample entropy
within the Alpha, Theta and Delta bands are most strongly correlated with the abilities, or
symptoms, measured in the ADOS-2, DAS-II and Vineland-II.
The correlations presented in Table 10 are remarkably consistent in terms of direction of
correlation across measures. Every significant correlation with ADOS-2 measures are negative,
suggesting that higher levels of sample entropy are related to lower ADOS-2 scores and less
symptomatology on this measure. Correlations with IQ and adaptive functioning are all positive,
indicating that higher levels of sample entropy are related to higher performance in these
domains. These results seem to suggest that higher levels of sample entropy in the locations and
frequency bands identified below are indicative of better functioning across psychological
domains and may help distinguish typical developing children and children diagnosed with ASD.
Notably absent from the correlations presented in Table 10 are any positive relationships
between sample entropy and verbal IQ, the measurement used to distinguish the ASDAvg and
ASDLow groups. This may help explain the lack of differences detected between the ASDAvg
and ASDLow discussed in Tables 11 – 16 below. Also important to note is the relative
infrequency of correlations between age and sample entropy. Correlations with age are found in
only 3 measurements, and in two of these age is the only attribute correlated within that
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measurement. While age appeared to be an important factor in our initial analysis, demonstrated
by its correlation with ADOS sores, it does not appear to be a significant factor in the sample
entropy portion of our analysis.
Table 10.1
Summary of Correlations Between Entropy and Assessment Scores
C4_4
F3_6
F4_6
F7_4
F7_6
F8_6
Fz_4
Fp1_4
Fp1_5
Fp2_4
Fp2_6
Row
C3_4
Frequency Scale Alpha
Alpha
Delta
Delta
Alpha
Delta
Delta
Alpha
Alpha
Theta
Alpha
Delta
Age
-0.293805573
0.353759846
ADOS_SA
-0.384789229 -0.293874332
-0.282332101 -0.338235322
ADOS_RRB
-0.315325566
-0.313480494
ADOS_Total
-0.281710832
-0.393193148 -0.310930561
-0.281713274
-0.287863962
ADOS_Comparison
-0.299826013
-0.375098686 -0.292085328
-0.32125593 -0.305878252 -0.354203646 -0.320622389
IQ_Verbal
IQ_Nonverbal
IQ_Spatial
0.406690464
IQ_GCA
IQ_SNC
Vineland_Comm
0.300035292 0.364403366
0.282001807
0.299420835
Vineland_DLS
0.297647331
Vineland_Soc
0.297902926 0.285309293 0.307060005
0.317175071
0.295369341

Tale 10.2
Summary of Correlations Between Entropy and Assessment Scores
T7_4
T7_5
P7_4
P8_4
Pz_4
Pz_5
P4_5
Pz_3
P3_5
P3_6
P4_2
P4_4
Row
P3_4
Alpha
Alpha
Theta
Alpha
Beta
Alpha
Theta
Gamma
Alpha
Theta
Frequency Scale Alpha
Theta
Delta
-0.298849466
Age
-0.407844333 -0.36660881
-0.314235224 -0.320895105 -0.302475922
ADOS_SA
-0.292377421
-0.290391313 -0.359160601
-0.289692668
-0.341572741
ADOS_RRB
-0.346271695
-0.354166529 -0.296820316
ADOS_Total
-0.312222506 -0.345983792
-0.398097401 -0.357284088
-0.350539837 -0.372218768
-0.308978085 -0.342987742
ADOS_Comparison
IQ_Verbal
IQ_Nonverbal
IQ_Spatial
0.303592445
0.320040613 0.307958542 0.321646005
IQ_GCA
0.296163955
IQ_SNC
0.318490201
0.32121917 0.33302196
Vineland_Comm
0.29969164 0.300701486
0.341155895 0.353219201
Vineland_DLS
0.299461493
0.295081067
Vineland_Soc
0.351154922
0.40897845 0.340980719

The ANOVA analysis proceeded in two steps. The first step involved comparing three
groups – Typ, ASDAvg, ASDLow at each of the 114 sample entropy measures to see if there are
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any differences between groups. This analysis identified 10 sample entropy measurements with
group differences. The second step involved comparing Typ, ASDAvg, ASDLow groups at each
of the ten measurements to identify significant differences. Of the 10 groups originally
identified, 6 had at least two groups that were significantly different.
Table 11
Entropy Comparison between Typically Developing Children, Children with ASD and Average
Verbal Ability, and Children with ASD and Low Verbal Ability at the Fp1 Theta Measurement.
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Table 12
Entropy Comparison between Typically Developing Children, Children with ASD and Average
Verbal Ability, and Children with ASD and Low Verbal Ability at the Fp2 Alpha Measurement.

Table 13
Entropy Comparison between Typically Developing Children, Children with ASD and Average
Verbal Ability, and Children with ASD and Low Verbal Ability at the O2 Theta Measurement.
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Table 14
Entropy Comparison between Typically Developing Children, Children with ASD and Average
Verbal Ability, and Children with ASD and Low Verbal Ability at the P4 Alpha Measurement.

Table 15
Entropy Comparison between Typically Developing Children, Children with ASD and Average
Verbal Ability, and Children with ASD and Low Verbal Ability at the P4 Theta Measurement.
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Table16
Entropy Comparison between Typically Developing Children, Children with ASD and Average
Verbal Ability, and Children with ASD and Low Verbal Ability at the Pz Alpha Measurement.

These results are interpreted with greater detail in the discussion section, however, it is
important to note a few important features. The first is that all groups belong to either the Alpha
or Theta band. This reinforces the conception that group differences are strongest within these
EEG frequency bands. Scalp locations are also consistent, with positive results primarily from
the prefrontal cortex and parietal lobes. The group differences displayed in Table 13 are
interesting for two reasons. First, the difference originates in the occipital lobe and there were no
correlations between psychological scores and sample entropy in the occipital lobe, as displayed
in Table 10. Second, Table 13 shows ASDAvg with lower sample entropy than both Typ and
ASDLow groups. This is inconsistent with all other ANOVA measures, and the correlations in
Table 10, which suggest that higher sample entropy is associated with typical development. The
prefrontal cortex and parietal lobe also play a more central role in the cognitive processes which
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tend to distinguish typically developing children and those diagnosed with ASD. Future studies
will be needed to confirm the significance of the results presented in Table 13.
Discussion
The sample used in this study appears representative of the broader population of
children with ASD in terms of sex and cognitive ability. Sex was not correlated with ASD
symptoms, adaptive functioning, or IQ, however, older children in the study appeared to have
been diagnosed with ASD at a higher rate than younger children in the sample. This irregularity
provides some challenges in interpreting our results and establishing the relationship between
sample entropy and ASD symptomatology.
Sample entropy was correlated with behavioral measures at 25 of the 114 possible
locations, with the majority occurring in Alpha, Theta, and Delta frequency bands. The ANOVA
analysis differentiated groups within Alpha and Theta frequency bands. The consistency with
which Alpha, Theta, and Delta frequencies generated positive results, in contrast with High
Gamma, Gamma, and Beta frequencies, suggests that sample entropy as a marker for ASD in
children is most significant within these frequency bands.
The direction of correlations was also consistent across our analysis. Higher levels of
entropy were almost universally associated with lower ASD symptomatology and better adaptive
functioning. Correlations in our analysis were moderate, ranging from .28 to .41 and were
predominantly found within ADOS-2 and Vineland-II scores. Sample entropy was infrequently
correlated with measures of intelligence and was never correlated with verbal IQ.
While all of the significant correlations in our study supported the conclusion that higher
levels of sample entropy are associated with lower ASD symptoms and better adaptive
functioning, one ANOVA result contradicted this trend. The results of the ANOVA for O2 Theta
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indicate that sample entropy is significantly higher for the ASDAvg group when compared to
both the Typ and ASDLow group. The limited number of participants in our study, along with
the high number of analysis performed, suggest that this result may be an anomaly within our
sample. Further research is needed to determine the veracity of this result, and determine if
sample entropy at the O2 theta measurement is significantly different for children with ASD and
average verbal ability.
Age was correlated with sample entropy in three instances, however, on two occasions it
was the only significant correlation, and it did not have a consistent direction of correlation as
found in behavioral measures. On two occasions lower sample entropy was correlated with
higher age, and on one occasion higher sample entropy was correlated with higher age. None of
the ANOVA analysis overlapped with significant age correlations. While future research may be
interested in exploring the relationship between sample entropy and age, it would appear that the
impact of the irregular relationship between age and ASD symptoms in our sample had little
impact on the analysis produced.
The results of our study suggest that sample entropy is not a measure capable of
identifying individuals with ASD and low verbal IQ. None of the six ANOVA measurements
successfully distinguished ASDLow from both the ASDAvg and Typ groups. Additionally,
sample entropy was not correlated with verbal IQ at any of 114 measurement points. While our
sample was small, and the cutoff for the ASDLow group was a verbal IQ of 85, as opposed to the
more common 70, researchers interested in identifying biomarkers of this subgroup may wish to
devote resources to alternative avenues of inquiry.
Our study did not demonstrate a relationship between sample entropy and the low verbal
subgroup of ASD, but it did demonstrate extensive and consistent correlations between sample
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entropy and both ASD symptoms and adaptive behavior. Our results suggest that lower levels of
sample entropy are correlated with higher levels of ASD symptoms and lower levels of adaptive
functioning. The consistency of these results across a multitude of observations could also be
interpreted as indicating that sample entropy is associated with a fundamental neurological
process found in ASD.
In addition to the correlational analysis, our ANOVA analysis demonstrated that children
diagnosed with ASD, of any verbal ability, can be distinguished from typically developing peers
based upon measures of sample entropy. These results confirm and extend the findings in Bosl et
al. (2011) which found that sample entropy could be used to distinguish infants and toddlers at
high risk of ASD from typically developing counterparts. Our findings have shown that sample
entropy may be used as a biomarker to identify ASD among older children, and also suggests
that sample entropy may be an indication of underlying neurological processes implicated in
ASD. The possibility that sample entropy is related to the etiology of ASD provides another line
of inquiry for researchers interested in greater understanding of this disorder.
The results of our ANOVA analysis indicate that ASD and typically developing peers
may be distinguished by sample entropy measurements in the prefrontal cortex and parietal lobe.
Abnormal processing in the prefrontal cortex has been implicated in ASD, specifically related to
core deficits in social cognition (Bicks, Koike, Akbarian, & Morishita, 2015; Paine, Swedlow, &
Swetschinski, 2017). Research into the role that sample entropy may play in the etiology of ASD
would benefit from replicating studies that use other methods to successfully identify
abnormalities in the prefrontal cortex. This would solidify sample entropy as an additional
measure to detect underlying neurological processes which contribute to ASD.
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Additional considerations for developing sample entropy as a useful measure of ASD
involve demonstrating the reliability and stability of this measurement. Reliability of sample
entropy measurements of EEG signals could be demonstrated by performing the same analysis
on multiple EEG measurements taken at the same time, and over the course of several weeks or
months. This would confirm that sample entropy is a reliable measurement of neurological
process and allow for longitudinal studies to establish how stable sample entropy is over time.
The stability of sample entropy could be established through measurements taken over
the course of years, and such studies would provide a baseline regarding the natural development
of sample entropy over the course of an individual’s life. Regarding ASD, this baseline would
allow for developmental trajectories of ASD, and typically developing peers which incorporate
sample entropy measurements in order to understand how this metric may differ between groups.
Incorporating sample entropy into these studies could also explore how sample entropy changes
in the course of behavioral treatment for ASD.
Our study has several limitations. First, our sample size of 49 was relatively small, and
conclusions drawn from our results are necessarily conservative. Further studies are needed to
verify the veracity of our findings. Second, our secondary data analysis precluded a better
understanding of participant demographics and treatment history. This limited the scope of our
initial analysis which provided a better understanding of the composition of our sample.
Despite these limitations, it appears that sample entropy may be a reliable measure of
autistic symptomatology for children between 4 and 11 years of age. These results confirm and
extend earlier applications of sample entropy to distinguish children at high risk of ASD from
typically developing counterparts (Bosl et al., 2011). Our results suggest that further research
into sample entropy is warranted to develop this measure into a viable aspect of future studies on
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ASD, particularly longitudinal studies attempting to identify developmental trajectories of
children with, and without, ASD.

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

50

References
Aman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., …
Vitiello, B. (2015). Tolerability, Safety, and Benefits of Risperidone in Children and
Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
Journal of Child and Adolescent Psychopharmacology, 25(6), 482–493.
https://doi.org/10.1089/cap.2015.0005
American Psychiatric Association. (2013). Diagnostic and
statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric
Publishing.
Anderson, D. K., Liang, J. W., & Lord, C. (2014). Predicting
young adult outcome among more and less cognitively able individuals with autism
spectrum disorders. Journal of Child Psychology and Psychiatry, 55(5), 485–494.
https://doi.org/10.1111/jcpp.12178
Billstedt, E., Gillberg, C., & Gillberg, C. (2005). Autism after adolescence: Population-based 13to 22-year follow-up study of 120 individuals with autism diagnosed in childhood.
Journal of Autism and Developmental Disorders, 35(3), 351–360.
http://doi.org/10.1007/s10803-005-3302-5
Bink, M., van Boxtel, G. J. M., Popma, A., Bongers, I. L., Denissen, A. J. M., & van
Nieuwenhuizen, C. (2015). EEG theta and beta power spectra in adolescents with ADHD
versus adolescents with ASD + ADHD. European Child & Adolescent Psychiatry, 24(8),
873–886. http://doi.org/10.1007/s00787-014-0632-x
Biswas, A. B., & Furniss, F. (2016). Cognitive phenotype and psychiatric disorder in 22q11.2
deletion syndrome: A review. Research in Developmental Disabilities, 53–54, 242–257.
http://doi.org/10.1016/j.ridd.2016.02.010
Bölte, S. (2014). Is autism curable? Developmental Medicine & Child Neurology, 56(10), 927–
931. http://doi.org/10.1111/dmcn.12495
Bondy, A., Esch, B. E., & Sundberg, M. (2010). Questions on verbal behavior and its application
to individuals with autism: An interview with the experts. The Behavior Analyst Today,
11(3), 186.
Bosl, W., Tierney, A., Tager-Flusberg, H., & Nelson, C. (2011). EEG complexity as a biomarker
for autism spectrum disorder risk. BMC Medicine, 9(1), 18.
Bosl, W., Loddenkemper, T., & Nelson, C. (Forthcoming). Nonlinear EEG biomarker reveals
commonalities and differences in autism and absence epilepsy. One Lucky Journal.

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

51

Boutros, N. N., Lajiness-O’Neill, R., Zillgitt, A., Richard, A. E., & Bowyer, S. M. (2015). EEG
changes associated with autistic spectrum disorders. Neuropsychiatric Electrophysiology,
1(1). http://doi.org/10.1186/s40810-014-0001-5
Bicks, L. K., Koike, H., Akbarian, S., & Morishita, H. (2015). Prefrontal Cortex and Social
Cognition in Mouse and Man. Frontiers in Psychology, 6.
https://doi.org/10.3389/fpsyg.2015.01805
Bruining, H., de Sonneville, L., Swaab, H., de Jonge, M., Kas, M., van Engeland, H., &
Vorstman, J. (2010). Dissecting the clinical heterogeneity of autism spectrum disorders
through defined genotypes. PLoS ONE, 5(5), e10887.
http://doi.org/10.1371/journal.pone.0010887
Cai, Q., Feng, L., & Yap, K. Z. (2018). Systematic review and meta-analysis of reported adverse
events of long-term intranasal oxytocin treatment for autism spectrum disorder: Intranasal
oxytocin adverse events. Psychiatry and Clinical Neurosciences, 72(3), 140–151.
https://doi.org/10.1111/pcn.12627
Cantio, C., Jepsen, J. R. M., Madsen, G. F., Bilenberg, N., & White, S. J. (2016). Exploring “The
autisms” at a cognitive level: Exploring “The Autisms” at a cognitive level. Autism
Research, 9(12), 1328–1339. https://doi.org/10.1002/aur.1630
Center for Disease Control and Prevention (2014). Prevalence of autism spectrum disorder
among children aged 8 years-autism and developmental disabilities monitoring network,
11 sites, United States, 2010. Morbidity and Mortality Weekly Report. Surveillance
Summaries (Washington, DC: 2002), 63, 1.
Chaste, P., Klei, L., Sanders, S. J., Hus, V., Murtha, M. T., Lowe, J. K., … Devlin, B. (2014). A
Genome-wide Association Study of Autism Using the Simons Simplex Collection: Does
Reducing Phenotypic Heterogeneity in Autism Increase Genetic Homogeneity?
Biological Psychiatry. http://doi.org/10.1016/j.biopsych.2014.09.017
Christensen DL, Baio J, Braun KV, et al. Prevalence and
Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism
and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012.
MMWR Surveill Summ 2016;65(No. SS-3)(No. SS-3):1–23
Cohen, D., Raffin, M., Canitano, R., Bodeau, N., Bonnot, O., Périsse, D., … Laurent, C. (2013).
Risperidone or aripiprazole in children and adolescents with autism and/or intellectual
disability: A Bayesian meta-analysis of efficacy and secondary effects. Research in
Autism Spectrum Disorders, 7(1), 167–175. https://doi.org/10.1016/j.rasd.2012.08.001
Costa, M., Goldberger, A. L., & Peng, C.-K. (2005). Multiscale
entropy analysis of biological signals. Physical Review E, 71(2).
https://doi.org/10.1103/PhysRevE.71.021906

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

52

Craig, F., Fanizza, I., Russo, L., Lucarelli, E., Alessandro, L., Pasca, M. G., & Trabacca, A.
(2017). Social communication in children with autism spectrum disorder (asd):
Correlation between DSM-5 and autism classification system of functioning-social
communication (ACSF:SC): The ACSF:SC in children with ASD. Autism Research,
10(7), 1249–1258. https://doi.org/10.1002/aur.1772
Crippa, A., Del Vecchio, G., Busti Ceccarelli, S., Nobile, M.,
Arrigoni, F., & Brambilla, P. (2016). Cortico-Cerebellar Connectivity in Autism
Spectrum Disorder: What Do We Know So Far? Frontiers in Psychiatry, 7.
https://doi.org/10.3389/fpsyt.2016.00020
Dawson, G., Rogers, S., Munson, J., Smith, M., Winter, J., Greenson, J., … Varley, J. (2010).
Randomized, Controlled Trial of an Intervention for Toddlers With Autism: The Early
Start Denver Model. PEDIATRICS, 125(1), e17–e23. https://doi.org/10.1542/peds.20090958
Dillenburger, K., & Keenan, M. (2009). None of the As in ABA stand for autism: Dispelling the
myths. Journal of Intellectual and Developmental Disability, 34(2), 193–195.
http://doi.org/10.1080/13668250902845244
Duifhuis, E. A., den Boer, J. C., Doornbos, A., Buitelaar, J. K., Oosterling, I. J., & Klip, H.
(2017). The Effect of Pivotal Response Treatment in Children with Autism Spectrum
Disorders: A Non-randomized Study with a Blinded Outcome Measure. Journal of
Autism and Developmental Disorders, 47(2), 231–242. https://doi.org/10.1007/s10803016-2916-0
Eigsti, I. M., & Schuh, J. M. (2008). Neurobiological underpinnings of language in autism
spectrum disorders. Annual Review of Applied Linguistics, 28, 128.
http://doi.org/10.1017/S0267190508080021
Eikeseth, S. (2009). Outcome of comprehensive psycho-educational interventions for young
children with autism. Research in Developmental Disabilities, 30(1), 158–178.
http://doi.org/10.1016/j.ridd.2008.02.003
El Achkar, C. M., & Spence, S. J. (2015). Clinical characteristics of children and young adults
with co-occurring autism spectrum disorder and epilepsy. Epilepsy & Behavior, 47, 183–
190. http://doi.org/10.1016/j.yebeh.2014.12.022
Elder, J., Kreider, C., Brasher, S., & Ansell, M. (2017). Clinical impact of early diagnosis of
autism on the prognosis and parent-child relationships. Psychology Research and
Behavior Management, Volume 10, 283–292. https://doi.org/10.2147/PRBM.S117499
Elliott, C. (2007). Differential Ability Scales, Second Edition. London, England: Pearson.
Erickson, C. A., Veenstra-Vanderweele, J. M., Melmed, R. D., McCracken, J. T., Ginsberg, L.
D., Sikich, L., … King, B. H. (2014). STX209 (Arbaclofen) for Autism Spectrum

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

53

Disorders: An 8-Week Open-Label Study. Journal of Autism and Developmental
Disorders, 44(4), 958–964. https://doi.org/10.1007/s10803-013-1963-z
Ewbank, M. P., Rhodes, G., von dem Hagen, E. H., Powell, T. E., Bright, N., Stoyanova, R. S.,
& ... Calder, A. J. (2015). Repetition suppression in ventral visual cortex is diminished as
a function of increasing autistic traits. Cerebral Cortex, 25(10), 3381-3393.
http://doi:10.1093/cercor/bhu149
Franklin, J. C., Jamieson, J. P., Glenn, C. R., & Nock, M. K. (2015). How developmental
psychopathology theory and research can inform the research domain criteria (RDoC)
Project. Journal of Clinical Child & Adolescent Psychology, 44(2), 280–290.
http://doi.org/10.1080/15374416.2013.873981
Foss-Feig, J. H., McPartland, J. C., Anticevic, A., & Wolf, J. (2016). Re-conceptualizing ASD
within a dimensional framework: Positive, negative, and cognitive feature clusters.
Journal of Autism and Developmental Disorders, 46(1), 342–351.
http://doi.org/10.1007/s10803-015-2539-x
Fossum, K.-L., Williams, L., Garon, N., Bryson, S. E., & Smith, M. (2018). Pivotal response
treatment for preschoolers with autism spectrum disorder: Defining a predictor profile:
PRT predictor profile. Autism Research, 11(1), 153–165. https://doi.org/10.1002/aur.1859
Fountain, C., Winter, A. S., & Bearman, P. S. (2012). Six Developmental Trajectories
Characterize Children With Autism.PEDIATRICS, 129(5), e1112–e1120.
https://doi.org/10.1542/peds.2011-1601
Georgiades, S., Szatmari, P., Boyle, M., Hanna, S., Duku, E., Zwaigenbaum, L., … Pathways in
ASD Study Team. (2013). Investigating phenotypic heterogeneity in children with autism
spectrum disorder: a factor mixture modeling approach: ASD factor mixture model.
Journal of Child Psychology and Psychiatry, 54(2), 206–215.
http://doi.org/10.1111/j.1469-7610.2012.02588.x
Gottfried, A. W., Gottfried, A. E., & Guerin, D. W. (2009).
Issues in early prediction and identification of intellectual giftedness. In F. D. Horowitz,
R. F. Subotnik, & D. J. Matthews (Eds.), The development of giftedness and talent across
the life span. (pp. 43–56). Washington: American Psychological Association. Retrieved
from http://content.apa.org/books/11867-003
Happé, F., Ronald, A., & Plomin, R. (2006). Time to give up on a single explanation for autism.
Nature Neuroscience, 9(10), 1218–1220. http://doi.org/10.1038/nn1770
Horgan, John. (2016, April 27) Claude Shannon: Tinkerer, prankster, and father of information
theory. Retrieved from https://spectrum.ieee.org/tech-history/cyberspace/claude-shannontinkerer-prankster-and-father-of-information-theory
Howlin, P., Goode, S., Hutton, J., & Rutter, M. (2004). Adult

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

54

outcome for children with autism. Journal of Child Psychology and Psychiatry, 45(2),
212–229.
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., … Wang, P. (2010).
Research domain criteria (RDoC): toward a new classification framework for research on
mental disorders. American Journal of Psychiatry. Retrieved from
http://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2010.09091379
Insel, T. R. (2014). Mental disorders in childhood: shifting the focus from behavioral symptoms
to neurodevelopmental trajectories. JAMA, 311(17), 1727–1728.
Jeste, S. S., & Tuchman, R. (2015). Autism spectrum disorder and epilepsy: Two sides of the
same coin? Journal of Child Neurology, 30(14), 1963–1971.
http://doi.org/10.1177/0883073815601501
Kanner, A. M. (2000). Commentary: the treatment of seizure disorders and EEG abnormalities in
children with autistic spectrum disorders: are we getting ahead of ourselves? Journal of
Autism and Developmental Disorders, 30(5), 491–495.
Keech, B., Crowe, S., & Hocking, D. R. (2018). Intranasal oxytocin, social cognition and
neurodevelopmental disorders: A meta-analysis. Psychoneuroendocrinology, 87, 9–19.
https://doi.org/10.1016/j.psyneuen.2017.09.022
Kim, S. H., Bal, V. H., & Lord, C. (2018). Longitudinal followup of academic achievement in children with autism from age 2 to 18. Journal of Child
Psychology and Psychiatry, 59(3), 258–267. https://doi.org/10.1111/jcpp.12808
Lazarev, V. V., Pontes, A., Mitrofanov, A. A., & deAzevedo, L. C. (2015). Reduced
Interhemispheric Connectivity in Childhood Autism Detected by
Electroencephalographic Photic Driving Coherence. Journal of Autism and
Developmental Disorders, 45(2), 537–547. https://doi.org/10.1007/s10803-013-1959-8
Lord, C., Bishop, S., & Anderson, D. (2015). Developmental
trajectories as autism phenotypes. American Journal of Medical Genetics Part C:
Seminars in Medical Genetics, 169(2), 198–208. https://doi.org/10.1002/ajmg.c.31440
Lord, C., Rutter, M., Dilavore, P. C., Risi, S., Gotham, K., Bishop, S. (2012) Autism Diagnostic
Observation Schedule, Second Edition. Torrance, CA: WPS
Lovaas, O. I. (1987). Behavioral treatment and normal educational and intellectual functioning in
young autistic children. Journal of Consulting and Clinical Psychology, 55(1), 3.
Machado, C., Estévez, M., Leisman, G., Melillo, R., Rodríguez, R., DeFina, P., … Beltrán, C.
(2015). QEEG spectral and coherence assessment of autistic children in three different
experimental conditions. Journal of Autism and Developmental Disorders, 45(2), 406–
424. http://doi.org/10.1007/s10803-013-1909-5

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

55

Magiati, I., Tay, X. W., & Howlin, P. (2012). Early comprehensive behaviorally based
interventions for children with autism spectrum disorders: a summary of findings from
recent reviews and meta-analyses. Neuropsychiatry, 2(6), 543–570.
http://doi.org/10.2217/npy.12.59
Maloney, A., Mick, E. O., & Frazier, J. (2014). Aripiprazole Decreases Irritability in 12 out of 14
Youth with Autism Spectrum Disorders. Journal of Child and Adolescent
Psychopharmacology, 24(6), 357–359. https://doi.org/10.1089/cap.2013.0143
Manning, M. A., Cassidy, S. B., Clericuzio, C., Cherry, A. M., Schwartz, S., Hudgins, L., …
Hoyme, H. E. (2004). Terminal 22q deletion syndrome: a newly recognized cause of
speech and language disability in the autism spectrum. Pediatrics, 114(2), 451–457.
Masi, A., Quintana, D. S., Glozier, N., Lloyd, A. R., Hickie, I. B., & Guastella, A. J. (2015).
Cytokine aberrations in autism spectrum disorder: A systematic review and metaanalysis. Molecular Psychiatry, 20(4), 440-446. http://doi:10.1038/mp.2014.59
Maxwell, C. R., Villalobos, M. E., Schultz, R. T., Herpertz-Dahlmann, B., Konrad, K., & Kohls,
G. (2015). Atypical laterality of resting gamma oscillations in autism spectrum disorders.
Journal of Autism and Developmental Disorders, 45(2), 292–297.
http://doi.org/10.1007/s10803-013-1842-7
McPartland, J. C. (2017). Developing clinically practicable biomarkers for autism spectrum
disorder. Journal of Autism and Developmental Disorders, Vol 47(9), 2935-2937.
Miyake, K., Hirasawa, T., Soutome, M., Itoh, M., Goto, Y., Endoh, K., … others. (2011). The
protocadherins, PCDHB1 and PCDH7, are regulated by MeCP2 in neuronal cells and
brain tissues: Implication for pathogenesis of rett syndrome. BMC Neuroscience, 12(1),
81.
Munshi, K. R., Gonzalez-Heydrich, J., Augenstein, T., & D’Angelo, E. J. (2011). Evidencebased treatment approach to autism spectrum disorders. Pediatric Annals, 40(11), 569–
574. http://doi.org/10.3928/00904481-20111007-08
Paine, T. A., Swedlow, N., & Swetschinski, L. (2017). Decreasing GABA function within the
medial prefrontal cortex or basolateral amygdala decreases sociability. Behavioural Brain
Research, 317, 542–552. https://doi.org/10.1016/j.bbr.2016.10.012
Peters-Scheffer, N., Didden, R., Korzilius, H., & Sturmey, P. (2011). A meta-analytic study on
the effectiveness of comprehensive ABA-based early intervention programs for children
with Autism Spectrum Disorders. Research in Autism Spectrum Disorders, 5(1), 60–69.
http://doi.org/10.1016/j.rasd.2010.03.011
Pina-Camacho, L., Villero, S., Boada, L., Fraguas, D., Janssen, J., Mayoral, M., … Parellada, M.
(2013). Structural magnetic resonance imaging data do not help support DSM-5 autism

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

56

spectrum disorder category. Research in Autism Spectrum Disorders, 7(2), 333–343.
http://doi.org/10.1016/j.rasd.2012.08.013
Rogers, S. J., Estes, A., Lord, C., Vismara, L., Winter, J., Fitzpatrick, A., … Dawson, G. (2012).
Effects of a brief Early Start Denver Model (ESDM)–based parent intervention on
toddlers at risk for autism spectrum disorders: A randomized controlled trial. Journal of
the American Academy of Child & Adolescent Psychiatry, 51(10), 1052–1065.
Ryberg, K. H. (2015). Evidence for the implementation of the Early Start Denver Model for
young children with autism spectrum disorder. Journal of the American Psychiatric
Nurses Association, 21(5), 327–337.
Saxe, G. N., Calderone, D., & Morales, L. J. (2018). Brain
entropy and human intelligence: A resting-state fMRI study. PLOS ONE, 13(2),
e0191582. https://doi.org/10.1371/journal.pone.0191582
Shannon, C. E. (1949). The Mathematical Theory of Communication.
Chicago, Illinois: University of Illinois Press.
Sivapalan, S., & Aitchison, K. J. (2014). Neurological Structure
Variations in Individuals with Autism Spectrum Disorder: a Review. Bulletin of Clinical
Psychopharmacology, 24(3), 268–275. https://doi.org/10.5455/bcp.20140903110206
Solomon, M., Ragland, J. D., Niendam, T. A., Lesh, T. A., Beck, J. S., Matter, J. C., & ... Carter,
C. S. (2015). Atypical learning in autism spectrum disorders: A functional magnetic
resonance imaging study of transitive inference. Journal of The American Academy of
Child & Adolescent Psychiatry, 54(11), 947-955. http://doi:10.1016/j.jaac.2015.08.010
Sparrow, S. S., Cicchetti, D. V. & Balla, D. A. (2005). Vineland Adaptive Behavior Scales,
Second Edition. London, England: Pearson
Spence, S. J., & Schneider, M. T. (2009). The role of epilepsy and epileptiform EEGs in autism
spectrum disorders. Pediatric Research, 65(6), 599–606.
Štefánik, P., Olexová, L., & Kršková, L. (2015). Increased sociability and gene expression of
oxytocin and its receptor in the brains of rats affected prenatally by valproic acid.
Pharmacology Biochemistry and Behavior, 131, 42–50.
https://doi.org/10.1016/j.pbb.2015.01.021
Stohn, J. P., Martinez, M. E., Zafer, M., López-Espíndola, D., Keyes, L. M., & Hernandez, A.
(2018). Increased aggression and lack of maternal behavior in Dio3-deficient mice are
associated with abnormalities in oxytocin and vasopressin systems: Dio3, neuropeptides
and social behavior. Genes, Brain and Behavior, 17(1), 23–35.
https://doi.org/10.1111/gbb.12400

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

57

Sullivan, P. F., Daly, M. J., & O’Donovan, M. (2012). Genetic architectures of psychiatric
disorders: the emerging picture and its implications. Nature Reviews Genetics, 13(8),
537–551. http://doi.org/10.1038/nrg3240
Sundberg, M. L. (2008) Verbal behavior milestones assessment and placement program: The
VB-MAPP. Concord, CA: AVB Press.
Tek, S., Mesite, L., Fein, D., & Naigles, L. (2014). Longitudinal analyses of expressive language
development reveal two distinct language profiles among young children with autism
spectrum disorders. Journal of Autism and Developmental Disorders, 44(1), 75–89.
http://doi.org/10.1007/s10803-013-1853-4
Tick, B., Bolton, P., Happé, F., Rutter, M., & Rijsdijk, F. (2016). Heritability of autism spectrum
disorders: a meta-analysis of twin studies. Journal of Child Psychology and Psychiatry,
57(5), 585–595. http://doi.org/10.1111/jcpp.12499
Tsai, L. Y., & Ghaziuddin, M. (2014). DSM-5 ASD moves forward into the past. Journal of
Autism and Developmental Disorders, 44(2), 321–330. http://doi.org/10.1007/s10803013-1870-3
van Heijst, B. F., & Geurts, H. M. (2015). Quality of life in
autism across the lifespan: A meta-analysis. Autism, 19(2),158–167.
Van Rijn, S. (2015). Social attention in 47,XXY (klinefelter syndrome): Visual ccanning of
facial expressions using eyetracking. Journal of the International Neuropsychological
Society, 21(5), 364–372. http://doi.org/10.1017/S1355617715000302
Venker, C. E., Ray-Subramanian, C. E., Bolt, D. M., & Weismer, S. E. (2014). Trajectories of
autism severity in early childhood. Journal of Autism and Developmental Disorders,
44(3), 546–563. http://doi.org/10.1007/s10803-013-1903-y
Ventola, P., Friedman, H. E., Anderson, L. C., Wolf, J. M., Oosting, D., Foss-Feig, J., …
Pelphrey, K. A. (2014). Improvements in Social and Adaptive Functioning Following
Short-Duration PRT Program: A Clinical Replication. Journal of Autism and
Developmental Disorders, 44(11), 2862–2870. https://doi.org/10.1007/s10803-014-21453
Ventola, P. E., Yang, D., Abdullahi, S. M., Paisley, C. A., Braconnier, M. L., & Sukhodolsky, D.
G. (2016). Brief Report: Reduced Restricted and Repetitive Behaviors after Pivotal
Response Treatment. Journal of Autism and Developmental Disorders, 46(8), 2813–
2820. https://doi.org/10.1007/s10803-016-2813-6
Ventola, P., Yang, D. Y. J., Friedman, H. E., Oosting, D., Wolf, J., Sukhodolsky, D. G., &
Pelphrey, K. A. (2015). Heterogeneity of neural mechanisms of response to pivotal
response treatment. Brain Imaging and Behavior, 9(1), 74–88.
http://doi.org/10.1007/s11682-014-9331-y

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

58

Vietze, P., & Lax, L. E. (2018). Early Intervention ABA for Toddlers with ASD: Effect of Age
and Amount. Current Psychology. https://doi.org/10.1007/s12144-018-9812-z
Viscidi, E. W., Johnson, A. L., Spence, S. J., Buka, S. L., Morrow, E. M., & Triche, E. W.
(2013). The association between epilepsy and autism symptoms and maladaptive
behaviors in children with autism spectrum disorder. Autism, 18(8), 996-1006.
Vissoker, R. E., Latzer, Y., & Gal, E. (2015). Eating and feeding problems and gastrointestinal
dysfunction in autism spectrum disorders. Research in Autism Spectrum Disorders, 12,
10–21. http://doi.org/10.1016/j.rasd.2014.12.010
Young, R. L., & Rodi, M. L. (2014). Redefining autism spectrum disorder using DSM-5: The
implications of the proposed DSM-5 criteria for autism spectrum disorders. Journal of
Autism and Developmental Disorders, 44(4), 758–765. http://doi.org/10.1007/s10803013-1927-3

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

Appendix A

59

ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD

Appendix B

Compile Data

Manually import original data file-by-file using Matlab
import function. This auto-formats table contents.
Contents
















Save imported data
Load Data
Implement CleanTables Function
Add Column to Identify Module/Version
Determine Dx, Language Level and combined
This Section has been commented-out because we are not using these features in this analysis
Select Total Scores
Rename Total Score Columns for DAS and ADOS, which allows for concatenation
Concatenate Versions of ADOS and DAS
Remove Duplicate Rows
Manually remove rows from Table flagged above
Join Tables
Determine Final Categories
Save Table
End

Save imported data
writetable(adi200304, 'adi.xlsx');
writetable(ados1201201, 'adosm1.xlsx');
writetable(ados2201201, 'adosm2.xlsx');
writetable(ados3201201, 'adosm3.xlsx');
writetable(dasiiearly03, 'dasey.xlsx');
writetable(dasiischool04, 'dassa.xlsx');
writetable(vinelandsurvey200505, 'vineland.xlsx');

Load Data
ADI = readtable('adi.xlsx');
ADOSm1 = readtable('adosm1.xlsx');
ADOSm2 = readtable('adosm2.xlsx');
ADOSm3 = readtable('adosm3.xlsx');
DASEY = readtable('dasey.xlsx');
DASSA = readtable('dassa.xlsx');
Vineland = readtable('vineland.xlsx');
EEG_Analysis = readtable('NDAR_data_SE_RQA.xlsx');

Implement CleanTables Function
This deletes redundant column headers and standardizes missing values.
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ADI = CleanTables(ADI);
ADOSm1 = CleanTables(ADOSm1);
ADOSm2 = CleanTables(ADOSm2);
ADOSm3 = CleanTables(ADOSm3);
DASEY = CleanTables(DASEY);
DASSA = CleanTables(DASSA);
Vineland = CleanTables(Vineland);

Add Column to Identify Module/Version
ADOSm1.Module(:, 1) = 1;
ADOSm2.Module(:, 1) = 2;
ADOSm3.Module(:, 1) = 3;
DASEY.Version(:,1) = "EY";
DASSA.Version(:,1) = "SA";

Determine Dx, Language Level and combined
%ADOS Module 1 Dx
for i = 1:height(ADOSm1)
if ADOSm1.scoresumm_compscore(i) >= 4
ADOSm1.Autism_Dx(i) = 1;
else
ADOSm1.Autism_Dx(i) = 0;
end
end
%ADOS Module 2 Dx
for i = 1:height(ADOSm2)
if ADOSm2.scoresumm_compscore(i) >= 4
ADOSm2.Autism_Dx(i) = 1;
else
ADOSm2.Autism_Dx(i) = 0;
end
end
%ADOS Module 3 Dx
for i = 1:height(ADOSm3)
if ADOSm3.scoresumm_compscore(i) >= 4
ADOSm3.Autism_Dx(i) = 1;
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else
ADOSm3.Autism_Dx(i) = 0;
end
end
%DAS EY Low IQ
for i = 1:height(DASEY)
if DASEY.dasii_eyr_verbal_ss(i) < 85
DASEY.Low_Verbal(i) = 1;
else
DASEY.Low_Verbal(i) = 0;
end
end
%DAS SA Low IQ
for i = 1:height(DASSA)
if DASSA.dasii_sar_verbal_ss(i) < 85
DASSA.Low_Verbal(i) = 1;
else
DASSA.Low_Verbal(i) = 0;
end
end

This Section has been commented-out because we are not using
these features in this analysis
%ADI Minimally Verbal for i = 1:height(ADI) if ADI.funccom_levell(i) == 2 ADI.Minimally_Verbal(i) = 1; else
ADI.Minimally_Verbal(i) = 0; end end %DAS SA Poor Expressive Language for i = 1:height(DASSA) if
ismissing(DASSA.dasii_sar_wdef_tscr(i)) DASSA.DAS_Poor_Expressive(i) = NaN; elseif
DASSA.dasii_sar_wdef_tscr(i) >=10 && DASSA.dasii_sar_wdef_tscr(i) <= 49 DASSA.DAS_Poor_Expressive(i) = 1;
else DASSA.DAS_Poor_Expressive(i) = 0; end end x = nan(height(DASEY)); % Initialize NaN matrix to add to
DASEY DASEY.DAS_Poor_Expressive = x; % Add column to DASEY to be consistent with DASSA %DAS SA Poor
Expressive Semantics for i = 1:height(DASSA) if ismissing(DASSA.dasii_sar_vsim_tscr(i))
DASSA.DAS_Poor_Expressive(i) = NaN; elseif DASSA.dasii_sar_vsim_tscr(i) >=10 &&
DASSA.dasii_sar_wdef_tscr(i) <= 50 DASSA.DAS_Poor_Expressive_Semantics(i) = 1; else
DASSA.DAS_Poor_Expressive_Semantics(i) = 0; end end DASEY.DAS_Poor_Expressive_Semantics = x; %Adds
column to DASEY to be consistent with DASSA

Select Total Scores
GUIDs and total scores with inerpretations for all - ADOS includes age and sex

ADI_Total = ADI(:, {'subjectkey', 'dbaes_atotal', 'dbaes_ctotal', 'dbaes_dtotal'});
ADOSm1_Total = ADOSm1(:, {'subjectkey', 'interview_age', 'gender',
'scoresumm2_abtotal', 'scoresumm_adtotal', ...
'scoresumm_overalltotal', 'scoresumm_compscore', 'Module', 'Autism_Dx'});
ADOSm2_Total = ADOSm2(:, {'subjectkey', 'interview_age', 'gender',
'scoresumm2_abtotal', 'scoresumm_adtotal', ...
'scoresumm_overalltotal', 'scoresumm_compscore', 'Module', 'Autism_Dx'});
ADOSm3_Total = ADOSm3(:, {'subjectkey', 'interview_age', 'gender',
'scoresumm2_abtotal', 'scoresumm_adtotal', ...
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'scoresumm_overalltotal', 'scoresumm_compscore', 'Module', 'Autism_Dx'});
DASEY_Total = DASEY(:, {'subjectkey', 'dasii_eyr_verbal_ss','dasii_eyr_nonverb_r_ss',
'dasii_eyr_spatial_ss', ...
'dasii_eyr_gca_ss', 'dasii_eyr_snc_ss', 'Version', 'Low_Verbal'});
DASSA_Total = DASSA(:, {'subjectkey', 'dasii_sar_verbal_ss','dasii_sar_nvr_ss',
'dasii_sar_spatial_ss', ...
'dasii_sar_gca_ss', 'dasii_sar_snc_ss', 'Version', 'Low_Verbal'});
Vineland_Total = Vineland(:, {'subjectkey', 'communicationdomain_total',
'livingskillsdomain_total', ...
'socializationdomain_total'});

Rename Total Score Columns for DAS and ADOS, which allows for
concatenation
DASEY_Total.Properties.VariableNames{'dasii_eyr_verbal_ss'} = 'Verbal';
DASEY_Total.Properties.VariableNames{'dasii_eyr_nonverb_r_ss'} = 'Nonverbal';
DASEY_Total.Properties.VariableNames{'dasii_eyr_spatial_ss'} = 'Spatial';
DASEY_Total.Properties.VariableNames{'dasii_eyr_gca_ss'} = 'GCA';
DASEY_Total.Properties.VariableNames{'dasii_eyr_snc_ss'} = 'SNC';
DASSA_Total.Properties.VariableNames{'dasii_sar_verbal_ss'} = 'Verbal';
DASSA_Total.Properties.VariableNames{'dasii_sar_nvr_ss'} = 'Nonverbal';
DASSA_Total.Properties.VariableNames{'dasii_sar_spatial_ss'} = 'Spatial';
DASSA_Total.Properties.VariableNames{'dasii_sar_gca_ss'} = 'GCA';
DASSA_Total.Properties.VariableNames{'dasii_sar_snc_ss'} = 'SNC';

Concatenate Versions of ADOS and DAS
ADOS_Total = vertcat(ADOSm1_Total, ADOSm2_Total, ADOSm3_Total);
DAS_Total = vertcat(DASEY_Total, DASSA_Total);

Remove Duplicate Rows
ADI_Total = RemoveDuplicateRows(ADI_Total);
ADOS_Total = RemoveDuplicateRows(ADOS_Total);
DAS_Total = RemoveDuplicateRows(DAS_Total);
Vineland_Total = RemoveDuplicateRows(Vineland_Total);

Manually remove rows from Table flagged above
NDARP351LEP
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DAS_Total.Verbal(12) = 80;
% Participant had verbal score from EY and
remaining scores from SA
DAS_Total.Version(12) = 'EY&SA';
DAS_Total.Low_Verbal(12) = DAS_Total.Low_Verbal(11); % Transfer Low_Verbal Category
with Vebal Score
DAS_Total = DAS_Total([1:10 12:end], :);
% NDARRC664GBF
DAS_Total = DAS_Total([1:27 29:end], :);
% Participant had EY scores but no SA
scores
% NDARTW441YZ7
DAS_Total.Verbal(31) = 87;
% Participant had much higher verbal score
from EY. I used this score and ...
DAS_Total.GCA(31) = NaN;
% kept others from SA, setting GCA to NaN.
Also changed low verbal.
DAS_Total.Version(31) = 'EY&SA';
DAS_Total.Low_Verbal(31) = DAS_Total.Low_Verbal(32); % Transfer Low_Verbal Category
with Vebal Score
DAS_Total = DAS_Total([1:31 33:end], :);
DAS_Total = RemoveDuplicateRows(DAS_Total); % Check for duplicate row warning

Join Tables
Total
Total
Total
Total

=
=
=
=

outerjoin(ADOS_Total, ADI_Total, 'MergeKeys', true);
outerjoin(Total, DAS_Total, 'MergeKeys', true);
outerjoin(Total, Vineland_Total, 'MergeKeys', true);
innerjoin(Total, EEG_Analysis);

Determine Final Categories
for i = 1:size(Total,1)
if Total.Autism_Dx(i) == 0 && Total.Low_Verbal(i) == 0
Total.Final_Cats(i) = 0;
elseif Total.Autism_Dx(i) == 1 && Total.Low_Verbal(i) == 0
Total.Final_Cats(i) = 1;
elseif Total.Autism_Dx(i) == 1 && Total.Low_Verbal(i) == 1
Total.Final_Cats(i) = 2;
elseif Total.Autism_Dx(i) == 0 && Total.Low_Verbal(i) == 1
Total.Final_Cats(i) = 4;
else
Total.Final_Cats(i) = NaN;
end
end
%Reorder with Final_Cats at end of scores
Total = Total(:, [1:22, end, 23:end-1]);

Save Table
writetable(Total, 'ScoresAndEEG.xlsx');
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End
Convert to Matrices
Contents







Load ScoresAndEEG
Separate Demographic Information and Scores
Convert Scores to Matrices
Convert EEG to Matrices
Clear unneeded variables
Save wokspace variables

Load ScoresAndEEG
ScoresAndEEG = readtable('ScoresAndEEG.xlsx');

Separate Demographic Information and Scores
GUID = ScoresAndEEG(:,{'subjectkey'});
Age = ScoresAndEEG(:,{'interview_age'});
Sex = ScoresAndEEG(:,{'gender'});
Diagnosis = ScoresAndEEG(:,{'Autism_Dx'});
ADOS_Module = ScoresAndEEG(:,{'Module'});
Low_Verbal = ScoresAndEEG(:,{'Low_Verbal'});
DAS_Version = ScoresAndEEG(:,{'Version'});
ADOS = ScoresAndEEG(:,{'scoresumm2_abtotal', 'scoresumm_adtotal',
'scoresumm_overalltotal', 'scoresumm_compscore'});
ADI = ScoresAndEEG(:,{'dbaes_atotal', 'dbaes_ctotal', 'dbaes_dtotal'});
IQ = ScoresAndEEG(:,{'Verbal', 'Nonverbal', 'Spatial', 'GCA', 'SNC'});
Vineland = ScoresAndEEG(:,{'communicationdomain_total', 'livingskillsdomain_total',
'socializationdomain_total'});
Final_Cats = ScoresAndEEG(:,{'Final_Cats'});

Convert Scores to Matrices
GUID = table2array(GUID);
Age = table2array(Age);
Sex = categorical(table2array(Sex));
Diagnosis = categorical(table2array(Diagnosis));
ADOS_Module = categorical(table2array(ADOS_Module));
Low_Verbal = categorical(table2array(Low_Verbal));
DAS_Version = categorical(table2array(DAS_Version));
ADOS = table2array(ADOS);
Module
ADI = table2array(ADI);
IQ = table2array(IQ);
GCA, SNC, DAS Version
Vineland = table2array(Vineland);
Skills, Socialization

%
%
%
%
%
%
%
%

NDAR Identifiers
In months, at time of ADOS
M/F as categorical
Dx as categorical
ADOS Module as categorical
Low verbal IQ as categorical
DAS Version as categorical
SA, RRB, Total, Comparison,

% Sections A, C, D
% Verbal, Nonverbal, Spatial,
% Communication, Daily Living
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% All combinations of ASD(+,-)

Convert EEG to Matrices
x = find(strcmpi(ScoresAndEEG.Properties.VariableNames,'SampE_C3_cD1')); % Find the
column number that begins EEG records
SampE = ScoresAndEEG(:, x: x+113);
SampE2D = table2array(SampE);
SampE3D = SortEEG(SampE2D);
SampE_VariableNames = ScoresAndEEG.Properties.VariableNames(x:x+113);

Clear unneeded variables
clear ScoresAndEEG
clear SampE
clear x

Save workspace variables
save('Variables.mat');

END
Result of Basic Psych Statistics
Contents









Load Variables
Subgroup Indexing
Run BasicStats on Complete Sample
Run BasicStats on TypAvgV
Run BasicStats on ASDAvgV
Run BasicStats on ASDLowV
Write results as table
End

Load Variables
clear
load('Variables.mat')

Subgroup Indexing
TypAvgV = find(Final_Cats == '0');
ASDAvgV = find(Final_Cats == '1');
ASDLowV = find(Final_Cats == '2');
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List_Full = {'Age', 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison', 'ADI_A',
'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ...
'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', 'Vineland_Comm', 'Vineland_DLS',
'Vineland_Soc'};

Run BasicStats on Complete Sample
a = BasicStats(Age);
b = BasicStats(ADOS);
c = BasicStats(ADI);
d = BasicStats(IQ);
e = BasicStats(Vineland);

Total_Psych_Stats = vertcat(a, b, c, d, e);
Total_Psych_Stats = array2table(Total_Psych_Stats);
Total_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean',
'Standard_Deviation'};
Total_Psych_Stats.Properties.RowNames = List_Full;

Run BasicStats on TypAvgV
a = BasicStats(Age(TypAvgV, :));
b = BasicStats(ADOS(TypAvgV, :));
c = BasicStats(ADI(TypAvgV, :));
d = BasicStats(IQ(TypAvgV, :));
e = BasicStats(Vineland(TypAvgV, :));

TypAvgV_Psych_Stats = vertcat(a, b, c, d, e);
TypAvgV_Psych_Stats = array2table(TypAvgV_Psych_Stats);
TypAvgV_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean',
'Standard_Deviation'};
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TypAvgV_Psych_Stats.Properties.RowNames = List_Full;

Run BasicStats on ASDAvgV
a = BasicStats(Age(ASDAvgV, :));
b = BasicStats(ADOS(ASDAvgV, :));
c = BasicStats(ADI(ASDAvgV, :));
d = BasicStats(IQ(ASDAvgV, :));
e = BasicStats(Vineland(ASDAvgV, :));

ASDAvgV_Psych_Stats = vertcat(a, b, c, d, e);
ASDAvgV_Psych_Stats = array2table(ASDAvgV_Psych_Stats);
ASDAvgV_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean',
'Standard_Deviation'};
ASDAvgV_Psych_Stats.Properties.RowNames = List_Full;

Run BasicStats on ASDLowV
a = BasicStats(Age(ASDLowV, :));
b = BasicStats(ADOS(ASDLowV, :));
c = BasicStats(ADI(ASDLowV, :));
d = BasicStats(IQ(ASDLowV, :));
e = BasicStats(Vineland(ASDLowV, :));

ASDLowV_Psych_Stats = vertcat(a, b, c, d, e);
ASDLowV_Psych_Stats = array2table(ASDLowV_Psych_Stats);
ASDLowV_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean',
'Standard_Deviation'};
ASDLowV_Psych_Stats.Properties.RowNames = List_Full;

Write results as table

68
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writetable(Total_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 'Full_Sample',
'WriteRowNames', true)
writetable(TypAvgV_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet',
'Typical_Avgerage_Verbal', 'WriteRowNames', true)
writetable(ASDAvgV_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet',
'ASD_Avgerage_Verbal', 'WriteRowNames', true)
writetable(ASDLowV_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 'ASD_Low_Verbal',
'WriteRowNames', true)
Error using writetable (line 124)
Unable to write to file 'Basic_Psych_Stats.xlsx'.
spreadsheet file and is not password protected.

Ensure the file is a valid

Error in Results_of_Basic_Psych_Statistics (line 56)
writetable(Total_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 'Full_Sample',
'WriteRowNames', true)

End
Results of Sex T-tests
Contents






Load Variables
Subgroup indexing by sex used in function SexTtest
Sex Ttest
Write Results as Table
End

Load Variables
clear
load('Variables.mat')

Subgroup indexing by sex used in function SexTtest
Malei = find(Sex == 'M');
% Male
Femalei = find(Sex == 'F');
% Female
List_Full = {'Age', 'Sex' 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison',
'Diagnosis', 'ADI_A', 'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ...
'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', ' Low_Verbal', 'Vineland_Comm', 'Vineland_DLS',
'Vineland_Soc', 'Final_Cats'};

Sex Ttest
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[Ttest, pvalue, ci, stats] = SexTtest(Age);
Run Age T-test
AgeSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = SexTtest(Sex);
Run Sex T-test
SexSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = SexTtest(ADOS);
Run ADOS T-test
ADOSSexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = SexTtest(Diagnosis);
Run Diagnosis T-test
DiagnosisSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = SexTtest(ADI);
Run ADI T-test
ADISexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = SexTtest(IQ);
Run IQ T-test
IQSexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

%

%

%

%

%

%

[Ttest, pvalue, ci, stats] = SexTtest(Low_Verbal);
%
Run Low_Verbal T-test
Low_VerbalSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate results
[Ttest, pvalue, ci, stats] = SexTtest(Vineland);
Run Vineland T-test
VinelandSexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%
%

[Ttest, pvalue, ci, stats] = SexTtest(Final_Cats);
%
Run Sex T-test
Final_CatsSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate Results
Sex_Ttest_Full = vertcat(AgeSexTtestResults, SexSexTtestResults, ADOSSexTtestResults,
DiagnosisSexTtestResults, ADISexTtestResults, ...
IQSexTtestResults, Low_VerbalSexTtestResults, VinelandSexTtestResults,
Final_CatsSexTtestResults);
% Verically Concatenate all results
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Sex_Ttest_Full = array2table(Sex_Ttest_Full);
% Convert to table
Sex_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high',
...
'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};
% Label Columns
Sex_Ttest_Full.Properties.RowNames = List_Full;

Write Results as Table
writetable(Sex_Ttest_Full, 'Sex_Ttest.xlsx', 'WriteRowNames', true)

End
Results of Age T-tests
Contents








Load Variables
Subgroup Indexing by age used in functions below
Young Med T-Tests
Young Old T-Tests
Med Old T-Tests
Write Results as Tables
end

Load Variables
clear
load('Variables.mat')

Subgroup Indexing by age used in functions below
Youngi = find(Age<74);
% Bottom 3rd
Medi = find(Age>=74 & Age<105);
% Middle 3rd
Oldi = find(Age>=105);
% Top 3rd
List_Full = {'Age', 'Sex', 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison',
'Diagnosis', 'ADI_A', 'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ...
'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', ' Low_Verbal', 'Vineland_Comm', 'Vineland_DLS',
'Vineland_Soc', 'Final_Cats'};

Young Med T-Tests
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Age);
% Run Age T-test
AgeYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Sex);
Run Sex T-test

%

%
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SexYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Young_Med_Ttest(ADOS);
Run ADOS T-test
ADOSYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Diagnosis);
Run Diagnosis T-test
DiagnosisYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = Young_Med_Ttest(ADI);
Run ADI T-test
ADIYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Young_Med_Ttest(IQ);
Run IQ T-test
IQYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

%

%

%

%

[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Low_Verbal);
%
Run Low_Verbal T-test
Low_VerbalYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate results
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Vineland);
Run Vineland T-test
VinelandYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%
%

[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Final_Cats);
%
Run Sex T-test
Final_CatsYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate Results
YM_Ttest_Full = vertcat(AgeYMTtestResults, SexYMTtestResults, ADOSYMTtestResults,
DiagnosisYMTtestResults, ADIYMTtestResults, ...
IQYMTtestResults, Low_VerbalYMTtestResults, VinelandYMTtestResults,
Final_CatsYMTtestResults);
% Verically Concatenate all results
YM_Ttest_Full = array2table(YM_Ttest_Full);
% Convert to table
YM_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high',
...
'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};
% Label Columns
YM_Ttest_Full.Properties.RowNames = List_Full;
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Young Old T-Tests
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Age);
% Run Age T-test
AgeYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Sex);
Run Sex T-test
SexYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Young_Old_Ttest(ADOS);
Run ADOS T-test
ADOSYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Diagnosis);
Run Diagnosis T-test
DiagnosisYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = Young_Old_Ttest(ADI);
Run ADI T-test
ADIYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Young_Old_Ttest(IQ);
Run IQ T-test
IQYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

%

%

%

%

%

[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Low_Verbal);
%
Run Low_Verbal T-test
Low_VerbalYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate results
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Vineland);
Run Vineland T-test
VinelandYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%
%

[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Final_Cats);
%
Run Sex T-test
Final_CatsYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate Results
YO_Ttest_Full = vertcat(AgeYOTtestResults, SexYOTtestResults, ADOSYOTtestResults,
DiagnosisYOTtestResults, ADIYOTtestResults, ...
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IQYOTtestResults, Low_VerbalYOTtestResults, VinelandYOTtestResults,
Final_CatsYOTtestResults);
% Verically Concatenate all results
YO_Ttest_Full = array2table(YO_Ttest_Full);
% Convert to table
YO_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high',
...
'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};
% Label Columns
YO_Ttest_Full.Properties.RowNames = List_Full;

Med Old T-Tests
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Age);
% Run Age T-test
AgeMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Sex);
Run Sex T-test
SexMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Med_Old_Ttest(ADOS);
Run ADOS T-test
ADOSMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Diagnosis);
Run Diagnosis T-test
DiagnosisMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = Med_Old_Ttest(ADI);
Run ADI T-test
ADIMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate Results

%

[Ttest, pvalue, ci, stats] = Med_Old_Ttest(IQ);
Run IQ T-test
IQMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

%

%

%

%

%

[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Low_Verbal);
%
Run Low_Verbal T-test
Low_VerbalMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate results
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Vineland);
Run Vineland T-test

%
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VinelandMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];
Concatenate results

%

[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Final_Cats);
%
Run Sex T-test
Final_CatsMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; %
Concatenate Results
MO_Ttest_Full = vertcat(AgeMOTtestResults, SexMOTtestResults, ADOSMOTtestResults,
DiagnosisMOTtestResults, ADIMOTtestResults, ...
IQMOTtestResults, Low_VerbalMOTtestResults, VinelandMOTtestResults,
Final_CatsMOTtestResults);
% Verically Concatenate all results
MO_Ttest_Full = array2table(MO_Ttest_Full);
% Convert to table
MO_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high',
...
'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};
% Label Columns
MO_Ttest_Full.Properties.RowNames = List_Full;

Write Results as Tables
writetable(YM_Ttest_Full, 'Age_Ttest.xlsx', 'sheet', 'Young_Medium', 'WriteRowNames',
true)
writetable(YO_Ttest_Full, 'Age_Ttest.xlsx', 'sheet', 'Young_Old', 'WriteRowNames',
true)
writetable(MO_Ttest_Full, 'Age_Ttest.xlsx', 'sheet', 'Medium_Old', 'WriteRowNames',
true)

End
Results of Psych Correlations
Contents







Load Variables
Run Correlation Between all Psych Scores
Isolate Statistically Significant Correlations
Convert to tables and only show correlations once - in upper half of tiangle
Write Table to File
end

Load Variables
clear
load('Variables.mat')
List_Full = {'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison', 'ADI_A', 'ADI_C',
'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ...
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'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', 'Vineland_Comm', 'Vineland_DLS', 'Vineland_Soc',
'Age'};

Run Correlation Between all Psych Scores
Don't change order of analysis, it is tied to the Psych_Correlation Function

[ADOSco, ADOSp] = Psych_Correlation(ADOS);
[ADIco, ADIp] = Psych_Correlation(ADI);
[IQco, IQp] = Psych_Correlation(IQ);
[Vinelandco, Vinelandp] = Psych_Correlation(Vineland);
[Ageco, Agep] = Psych_Correlation(Age);

% Concatenate all correlations and all p-values into two separate matrices
Correlations = vertcat(ADOSco, ADIco, IQco, Vinelandco, Ageco);
p_Values = vertcat(ADOSp, ADIp, IQp, Vinelandp, Agep);

Isolate Statistically Significant Correlations
keep correlations with p-values less than .05 and replace all correlations and p-values with NaN

Sig_p_Values = p_Values;
Sig_Correlations = Correlations;
for i = 1:size(Correlations, 1)
for j = 1:size(Correlations, 2)
if Sig_p_Values(i,j)> .05
Sig_p_Values(i,j) = (NaN);
Sig_Correlations(i,j) = (NaN);
end
end
end

Convert to tables and only show correlations once - in upper half of
tiangle
Sig_Correlations = triu(Sig_Correlations);
displayed twice in square, this isolates upper half
Sig_p_Values = triu(Sig_p_Values);

% Correlation and p-Values
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Sig_Correlations = array2table(Sig_Correlations);
Sig_p_Values = array2table(Sig_p_Values);

% Convert to table

Sig_Correlations.Properties.VariableNames = List_Full;
Sig_Correlations.Properties.RowNames = List_Full;

% Add column and row names

Sig_p_Values.Properties.VariableNames = List_Full;
Sig_p_Values.Properties.RowNames = List_Full;

% Add column and row names

Write Table to File
writetable(Sig_Correlations,'Psych_Correlations.xlsx', 'sheet', 'Correlations',
'WriteRowNames', true);
writetable(Sig_p_Values,'Psych_Correlations.xlsx', 'sheet', 'p_values',
'WriteRowNames', true);

End
Sample Entropy and Psych Scores Correlation
Contents









Load Variables
Correlations Psych Scores and SampE
Only Significant
Add Frequency Scale to First Row
Create Tables
Condense Columns to EEG Scalp Locations
Write as Tables
End

Load Variables
clear
load('Variables.mat')
List_Full = {'Frequency Scale' 'Age', 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total',
'ADOS_Comparison', 'ADI_A', 'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ...
'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', 'Vineland_Comm', 'Vineland_DLS',
'Vineland_Soc'};

Correlations Psych Scores and SampE
[Ageco, Agep] = corr(Age, SampE2D, 'rows', 'complete');
[ADOSco, ADOSp] = corr(ADOS, SampE2D, 'rows', 'complete');
[ADIco, ADIp] = corr(ADI, SampE2D,'rows', 'complete');
[IQco, IQp] = corr(IQ, SampE2D, 'rows', 'complete');
[Vinelandco, Vinelandp] = corr(Vineland, SampE2D, 'rows', 'complete');
FullCorrelation = vertcat(Ageco, ADOSco, ADIco, IQco, Vinelandco);
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FullP = vertcat(Ageco, ADOSp, ADIp, IQp, Vinelandp);

Only Significant
for i = 1:size(FullP,1)
for j = 1:size(FullP,2)
if FullP(i,j)> .05
FullP(i,j) = NaN;
FullCorrelation(i,j) = NaN;
end
end
end

Add Frequency Scale to First Row
FullCorrelation(2:17,:) = FullCorrelation(1:16,:);
FullP(2:17,:) = FullP(1:16,:);
for i = 1:6
if i == 1
zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "High Gamma";
elseif i == 2
zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Gamma";
elseif i == 3
zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Beta";
elseif i == 4
zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Alpha";
elseif i == 5
zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Theta";
elseif i == 6
zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Delta";
end
end
FullCorrelation = num2cell(FullCorrelation);
FullP = num2cell(FullP);
for i = 1:114
FullCorrelation{1,i} = zz{1,i};
FullP{1,i} = zz{1,i};
end

Create Tables
convert correlation coeficients to Table
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FullCorrelation = array2table(FullCorrelation);
FullCorrelation.Properties.VariableNames = SampE_VariableNames;
FullCorrelation.Properties.RowNames = List_Full;

FullP = array2table(FullP);
FullP.Properties.VariableNames = SampE_VariableNames;
FullP.Properties.RowNames = List_Full;

Condense Columns to EEG Scalp Locations
write new columns

FullCorrelation.C3 = FullCorrelation{:,1:6};
FullCorrelation.C4 = FullCorrelation{:,7:12};
FullCorrelation.O1 = FullCorrelation{:,13:18};
FullCorrelation.O2 = FullCorrelation{:,19:24};
FullCorrelation.Cz = FullCorrelation{:,25:30};
FullCorrelation.F3 = FullCorrelation{:,31:36};
FullCorrelation.F4 = FullCorrelation{:,37:42};
FullCorrelation.F7 = FullCorrelation{:,43:48};
FullCorrelation.F8 = FullCorrelation{:,49:54};
FullCorrelation.Fz = FullCorrelation{:,55:60};
FullCorrelation.Fp1 = FullCorrelation{:,61:66};
FullCorrelation.Fp2 = FullCorrelation{:,67:72};
FullCorrelation.P3 = FullCorrelation{:,73:78};
FullCorrelation.P4 = FullCorrelation{:,79:84};
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FullCorrelation.Pz = FullCorrelation{:,85:90};
FullCorrelation.T7 = FullCorrelation{:,91:96};
FullCorrelation.T8 = FullCorrelation{:,97:102};
FullCorrelation.P7 = FullCorrelation{:,103:108};
FullCorrelation.P8 = FullCorrelation{:,109:114};

FullP.C3 = FullP{:,1:6};
FullP.C4 = FullP{:,7:12};
FullP.O1 = FullP{:,13:18};
FullP.O2 = FullP{:,19:24};
FullP.Cz = FullP{:,25:30};
FullP.F3 = FullP{:,31:36};
FullP.F4 = FullP{:,37:42};
FullP.F7 = FullP{:,43:48};
FullP.F8 = FullP{:,49:54};
FullP.Fz = FullP{:,55:60};
FullP.Fp1 = FullP{:,61:66};
FullP.Fp2 = FullP{:,67:72};
FullP.P3 = FullP{:,73:78};
FullP.P4 = FullP{:,79:84};
FullP.Pz = FullP{:,85:90};
FullP.T7 = FullP{:,91:96};
FullP.T8 = FullP{:,97:102};
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FullP.P7 = FullP{:,103:108};
FullP.P8 = FullP{:,109:114};
% Delete old rows
FullCorrelation(:,1:114) = [];
FullP(:,1:114) = [];

Write as Tables
writetable(FullCorrelation,'Psych_Scores_And_EEG_Correlation.xlsx', 'sheet',
'Correlations', 'WriteRowNames', true);
writetable(FullP,'Psych_Scores_And_EEG_Correlation.xlsx', 'sheet', 'p_values',
'WriteRowNames', true);

End
ANOVA Analysis
Contents







Load Variables
Subgroup Indexing by age used in functions below
List of EEG Locations
ANOVA
Write Table
End

Load Variables
clear
load('Variables.mat')

Subgroup Indexing by age used in functions below
TypAvgVi = find(Final_Cats == '0');
Verbal IQ
ASDAvgVi = find(Final_Cats == '1');
Verbal IQ
ASDLowVi = find(Final_Cats == '2');
TypAvgEEG = SampE2D(TypAvgVi, :);
ASDAvgEEG = SampE2D(ASDAvgVi, :);
ASDLowEEG = SampE2D(ASDLowVi, :);

List of EEG Locations
for i = 1:6
if i == 1

% No ASD + Average or High
% ASD DX + Average or High
% ASD DX + Low Verbal IQ
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zz(1,[i, i+6,
i+6*11 i+6*12
elseif i == 2
zz(1,[i, i+6,
i+6*11 i+6*12
elseif i == 3
zz(1,[i, i+6,
i+6*11 i+6*12
elseif i == 4
zz(1,[i, i+6,
i+6*11 i+6*12
elseif i == 5
zz(1,[i, i+6,
i+6*11 i+6*12
elseif i == 6
zz(1,[i, i+6,
i+6*11 i+6*12
end
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i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "High Gamma";
i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Gamma";
i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Beta";
i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Alpha";
i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Theta";
i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ...
i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Delta";

end
for i = 1:114
if (i>=1) && (i<=6)
zz(1,i) = strcat('C3_', zz(1,i));
elseif (i>=1+6) && (i<=6*2)
zz(1,i) = strcat('C4_', zz(1,i));
elseif (i>=1+6*2) && (i<=6*3)
zz(1,i) = strcat('O1_', zz(1,i));
elseif (i>=1+6*3) && (i<=6*4)
zz(1,i) = strcat('O2_', zz(1,i));
elseif (i>=1+6*4) && (i<=6*5)
zz(1,i) = strcat('Cz_', zz(1,i));
elseif (i>=1+6*5) && (i<=6*6)
zz(1,i) = strcat('F3_', zz(1,i));
elseif (i>=1+6*6) && (i<=6*7)
zz(1,i) = strcat('F4_', zz(1,i));
elseif (i>=1+6*7) && (i<=6*8)
zz(1,i) = strcat('F7_', zz(1,i));
elseif (i>=1+6*8) && (i<=6*9)
zz(1,i) = strcat('F8_', zz(1,i));
elseif (i>=1+6*9) && (i<=6*10)
zz(1,i) = strcat('Fz_', zz(1,i));
elseif (i>=1+6*10) && (i<=6*11)
zz(1,i) = strcat('Fp1_', zz(1,i));
elseif (i>=1+6*11) && (i<=6*12)
zz(1,i) = strcat('Fp2_', zz(1,i));
elseif (i>=1+6*12) && (i<=6*13)
zz(1,i) = strcat('P3_', zz(1,i));
elseif (i>=1+6*13) && (i<=6*14)
zz(1,i) = strcat('P4_', zz(1,i));
elseif (i>=1+6*14) && (i<=6*15)
zz(1,i) = strcat('Pz_', zz(1,i));
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elseif (i>=1+6*15) && (i<=6*16)
zz(1,i) = strcat('T7_', zz(1,i));
elseif (i>=1+6*16) && (i<=6*17)
zz(1,i) = strcat('T8_', zz(1,i));
elseif (i>=1+6*17) && (i<=6*18)
zz(1,i) = strcat('P7_', zz(1,i));
elseif (i>=1+6*18) && (i<=6*19)
zz(1,i) = strcat('P8_', zz(1,i));
end
end

ANOVA
bb = NaN(10,1);
cc = NaN(19,1);
anovaTable = ["EEG_Location", "ANOVA_p-value", "MeanDiff/p-value", "Typ_ASDAvg",
"Typ_ASDLow", "ASDAvg_ASDLow"]';
for i = 1:114
a = TypAvgEEG(:, i);
b = vertcat(ASDAvgEEG(:, i), bb);
c = vertcat(ASDLowEEG(:,i), cc);
d = [a,b,c];
[p,~,stats] = anova1(d, [], 'off');
if p <= 0.05
[p,~,stats] = anova1(d);
[e,~,h,gnames] = multcompare(stats);
figure(h)
yticklabels({'ASD Low Verbal', 'ASD Avg Verbal', 'Typically Developing'});
f = [gnames(e(:,1)), gnames(e(:,2)), num2cell(e(:,3:6))];
g = vertcat(zz(1,i),p, "MeanDiff", f(:,3));
h = vertcat(NaN, NaN, "p-value", f(:,6));
anovaTable = [anovaTable, g, h];
end
end

Write Table
t = array2table(anovaTable);
writetable(t, 'Anova_Results.xlsx');

End

